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Primary myelofibrosis (PMF) is a proliferative disease of the bone marrow which is 
characterized by the presence of somatic, acquired mutation in hematopoietic stem 
cells, a resulting proliferation of cells of the megakaryocytic lineage and, as the 
primary disease manifestation, progressive bone marrow fibrosis. The mechanisms 
leading to myelofibrosis are largely unknown, however, prevailing evidence 
suggests a decisive role of platelet-derived growth factors (PDGFs) and their 
cognate receptors. Using the Gata-1low mouse model for PMF, this study aimed at 
characterizing expression, activation and regulation of PDGF receptor β (PDGFRβ) 
in different stages of the disease. RNAsequencing, qPCR, protein expression 
analyses, multiplexed immunohistochemistry and, as a novel approach in bone 
marrow tissue, an in situ proximity ligation assay (PLA) was applied to provide a 
detailed characterization of PDGFRβ signaling and regulation during development 
of myelofibrosis. Therefore, murine bone marrow was analyzed the at a pre-, an 
early, and an overt fibrotic stage. An increase in gene and protein expression of the 
PDGF signaling components in early and overt fibrotic bone marrow, and a cell-
type-specific expression of the ligands and the receptors was detected. PDGFRα 
expression was predominantly seen in megakaryocytes, whereas PDGFRβ was 
expressed in fibroblast, underlining the important role of PDGFRβ in fibroblast 
proliferation within disease development. PDGFRβ and PDGF-B protein expression 
was enhanced in overt fibrotic bone marrow, along with an increase in PDGFRβ–
PDGF-B interaction, analyzed by PLA. However, PDGFRβ tyrosine phosphorylation 
levels were not elevated. Hence, further analyses focused on regulation of PDGFRβ 
by protein tyrosine phosphatases (PTPs) as endogenous PDGFRβ antagonists. 
Gene expression analyses showed distinct expression dynamics among PDGFRβ-
targeting PTPs. In particular, enhanced T-cell PTP (TC-PTP) protein expression 
and PDGFRβ–TC-PTP interaction was observed in early and overt fibrotic bone 
marrow of Gata-1low mice. In vitro, TC-PTP (Ptpn2) knockdown increased PDGFRβ 
phosphorylation at Y751 and Y1021, leading to enhanced downstream AKT and 
phospholipase C γ1 (PLCγ1) activation in fibroblasts. Further, Ptpn2 knockdown 
cells showed increased growth rates when exposed to low-serum growth medium. 
Taken together, this study provides detailed insights into PDGF signaling during 
PMF development and suggests PTPs as novel, and so far unrecognized 
components in PMF.  
xi 
Zusammenfassung 
Die primäre Myelofibrose (PMF) ist eine proliferative Erkrankung des Knochen-
marks, die durch Mutationen in hämatopoetischen Stammzellen verursacht wird. 
Als Konsequenz kommt es zur Proliferation unreifer Megakaryozytenvorläuferzellen 
und zur Knochenmarksfibrose. Die zugrundeliegenden Mechanismen sind bislang 
unklar, die Forschung der letzten Jahre deutet allerdings daraufhin, dass 
Wachstumsfaktoren der Platelet-Derived Growth Factor (PDGF) Familie, sowie ihre 
Rezeptoren, eine entscheidende Rolle bei der Entstehung der PMF spielen. Diese 
Arbeit hatte zum Ziel, die Expression, Aktivierung sowie die Regulation des PDGF 
Rezeptor β (PDGFRβ) mithilfe des Gata-1low Mausmodells für PMF detailliert zu 
charakterisieren. Dabei wurden Gen- und Proteinexpressionsanalysen, Multiplexed 
Immunohistochemistry, sowie ein erstmalig im Knochenmark angewandter 
Proximity Ligation Assay (PLA) zur Analyse von Protein-Protein-Interaktion und 
Proteinphosphorylierung in situ genutzt, um Mäuse in einem prä-, einem frühen 
sowie einem fibrotischen Stadium zu untersuchen. Es konnte eine erhöhte Gen- 
und Proteinexpression von PDGF-A und PDGF-B, sowie beider Rezeptoren in einer 
frühen und fortgeschrittenen PMF nachgewiesen werden. Dabei wurde PDGFRβ 
fast ausschließlich in Knochenmarksfibroblasten detektiert. In früher sowie in der 
fortgeschrittenen Knochenmarksfibrose waren PDGFRβ und PDGF-B Protein-
expression deutlich erhöht, und damit verbunden konnte eine erhöhte Interaktion 
von Rezeptor und Ligand mittels in situ PLA nachgewiesen werden. Eine vermehrte 
Tyrosin-Phosphorylierung des Rezeptors war nicht detektierbar. Die Arbeit kon-
zentrierte sich daher weiterhin auf die enzymatische Gruppe der Protein-Tyrosin-
Phosphatasen (PTPs), welche PDGFRβ durch Dephosphorylierung regulieren. 
Genexpressionsanalysen zeigten sehr unterschiedliche Expressions-dynamiken 
der unterschiedlichen PTPs, insbesondere konnte eine erhöhte Expression der 
T cell PTP (TC-PTP) beobachtet werden. Die Interaktion von PDGFRβ und TC-PTP 
war in früher und fortgeschrittener Fibrose nachweislich erhöht. In vitro führte 
TC-PTP (Ptpn2) Knockdown in Fibroblasten zu vermehrter PDGFRβ Y751 und Y1021-
Phosphorylierung, damit verbunden war eine erhöhte AKT und Phospholipase C γ1 
(PLCγ1) Aktivierung. Desweiteren zeigten Ptpn2 Knockdown Zellen eine höhere 
Proliferation unter nährstofflimitierten Bedingungen. Zusammenfassend wurden in 
dieser Arbeit Komponenten des PDGF Systems charakterisiert, sowie PTPs als 
neue, bislang unberücksichtigte Komponenten in der PMF nachgewiesen. 
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1 INTRODUCTION 
1.1 Hematopoiesis and the bone marrow 
Blood cells have a limited live span and new blood cells are formed from a common 
precursor cell, a process referred to as hematopoiesis.1 In adult mammals, the bone 
marrow is the major blood-forming organ, which resides in the medulla of axial and 
long bones.2 The bone marrow consists of a wide variety of different cell types, and 
presents a mixture of cells in different states of differentiation (Figure 1.1). 
Hematopoietic stem cells (HSCs) and mesenchymal stromal cells (MSCs) are the 
two central cell entities which give rise to differentiated cells. 
As a defining feature, HSCs are able to differentiate into all blood and immune cells 
and have an indefinite self-renewal capacity.1 Importantly, HSCs can rescue effects 
of lethal irradiation,3 and are thus capable of reconstituting the blood system of entire 
organisms. This serves as the biological base for the regeneration of blood systems 
by stem cell transplantation. HSCs differentiate into lymphoid precursors, with the 
ability to further mature into B lymphocytes, T lymphocytes and natural killer cells, 
and myeloid precursors, giving rise to granulocytes, erythrocytes, monocytes and 
megakaryocytes.4 
MSCs can differentiate into cells that form the bone marrow stroma as a scaffold. 
MSCs have multipotent differentiation characteristics and can mature into 
adipocytes, chondrocytes, osteoblasts and myogenic cells.5-7 Due to their stem cell-
like differentiation potential, these cells have previously been referred to as 
‘mesenchymal stem cells’. However, there is no evidence that MSCs have unlimited 
self-renewal potential and MSCs do not possess transplantation characteristics that 
are comparable to HSCs.8 In fact, data indicate that MSCs are a heterogeneous pool 
of immature progenitor cells without a clearly defined immunophenotype. Hence, it 
has been disputed if MSCs qualify as ‘stem cells’,9,10 and ‘mesenchymal stromal 
cells’ is the preferred terminology to more accurately reflect their functional role as 
connective tissue and scaffolding cells. 
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Figure 1.1: Cells within the bone marrow. Hematopoietic stem cells (HSCs) can differentiate into all mature 
blood cells of the lymphoid lineage (B cells, T cells and natural killer (NK) cells) and the myeloid lineage 
(monocytes, granulocytes, megakaryocytes and erythrocytes). Mesenchymal stromal cells (MSCs) give rise to 
scaffolding cells, such as osteoblasts, chondrocytes, adipocytes and myogenic cells .[*] 
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While both HSCs and MSCs share a mesodermal origin,11,12 it is largely accepted 
that HSCs and MSCs present two distinct lineage entities. The classical model of 
hematopoiesis summarizes research from more than one century, since A. Maxilow 
postulated that blood cells are formed from one progenitor cell in 1909.13 This 
monophyletic model suggests a clear hierarchy and branching lineage directions, 
nevertheless, the origin of many cell types is still not known. For example, it has long 
been assumed that MSCs, which have a fibroblast-like phenotype, and mature 
fibroblasts are derived from a similar lineage.14,15 Transplantation experiments, 
however, indicate that fibroblasts have an HSC origin.16 In fact, differentiation 
patterns are not always straight forward and additional mechanisms, such as trans-, 
de- and re-differentiation, might contribute to cell maturation.17-19 
Differentiation, quiescence and self-renewal are tightly regulated processes, which 
rely on growth factors, cytokines, cell-cell interactions, extracellular matrix 
components and many other factors.20,21 HSCs are strongly dependent on their 
surrounding cells and microenvironment, also referred to as their niche.22-24 Hence, 
the different cells are not randomly distributed within the bone marrow but reside in 
specialized bone marrow niches. Undifferentiated HSCs, for example, preferably 
reside in the osteoblast niche or near blood vessel, referred to as the vascular 
niche.25,26 A multitude of external factors establish a controlled balance between 
differentiation and self-renewal of HSCs, however, the disruption of this balance can 
result in the development of a variety of proliferative malignancies. 
1.2 Myeloproliferative Neoplasms 
The common defining feature of myeloproliferative neoplasms (MPNs) is the clonal 
expansion of at least one cell type of the myeloid lineage, leading to an impaired 
hematopoietic function of the bone marrow. The classification of MPNs was revised 
by the World Health Organization (WHO) in 2016 (Table 1.1).27 Leukemia, 
characterized by the proliferation of granulocytes,28 is represented by three MPN 
subtypes: chronic myeloid leukemia (CML), characterized by the presence of the 
breakpoint cluster region-abelson (BCR-ABL) fusion oncogene,29 chronic 
neutrophilic leukemia and chronic eosinophilic leukemia. Three further MPNs have 
been specified: essential thrombocythemia (ET), polycythemia vera (PV) and primary 
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myelofibrosis (PMF). As the latter three MPNs share common driver mutations and 
underlying mechanisms, these three are often subgrouped as ‘classical, BCR-ABL-
negative MPNs’ (highlighted in Table 1.1). Nevertheless, those diseases present very 
distinct clinical features. Whereas ET and PV are characterized by platelet and 
erythrocyte overproduction, respectively, PMF is marked by aberrant proliferation of 
cells of the megakaryocytic lineage and, as the ‘primary’ disease manifestation, 
progressive bone marrow fibrosis. Both ET and PV can evolve into ‘secondary’ 
myelofibrosis and all three MPN subtypes can transform into acute myeloid leukemia 
(AML).30  
Table 1.1: Classification of myeloproliferative neoplasms (MPNs) by revised 2016 WHO criteria and frequently 
occurring driver mutations. 
MPN Driver mutations (frequencies) 
  
Chronic neutrophilic leukemia CSF3R (59%)31 
  
Chronic eosinophilic leukemia, 
not otherwise specified 
ASXL1, CSF3R, SETBP1 and    
others32 
  






















Essential thrombocythemia (ET) 


















Polycythemia vera (PV) JAK2 (97-98%)34,36 
Primary myelofibrosis (PMF) 








All MPNs are initiated by acquired, somatic mutations. Nevertheless, with the 
exception of BCR-ABL in CML28 and colony-stimulating factor 3 receptor (CSF3R) in 
chronic neutrophilic leukemia,31 driver mutations are not unique for the respective 
MPN subtypes. Especially the classical, BCR-ABL-negative MPNs cannot yet be 
genetically distinguished and the mechanisms directing the cells towards their 
specific, disease-defining phenotype remain unknown. 
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In the classical, BCR-ABL-negative MPNs, a driver mutation in one cell is sufficient 
to initiate the disease.40 Which cell presents the malignant origin has been 
extensively analyzed. Acquired mutations can be detected in mature cells41 but also 
in the HSCs at the top of the hierarchy,42,43 indicating that HSCs are the original 
malign cells. This supports the hypothesis that an undifferentiated HSC acquires a 
somatic driver mutation, which consequently promotes proliferation and 
differentiation in a myeloid direction.44 
1.3 Primary myelofibrosis  
Fibrosis is an essential part of tissue repair processes in response to injury. 
Fibroblasts, myofibroblasts and pericytes play a key role in fibrosis, as they produce 
collagens and other extracellular matrix (ECM) proteins and respond to cytokines, 
chemokines, and other mediators of inflammation.45 Fibrosis, however, is 
characterized by expansion of activated fibroblasts and extensive formation of ECM 
components, becoming irreversible and potentially leading to the loss of tissue 
function.46 Chronic and slowly progressing diseases are frequently accompanied by 
fibrosis, and virtually any organ can be affected by fibrotic changes.47 Anti-fibrosis 
treatment is typically anti-inflammatory and organ-specific; however, established 
treatment strategies for fibrosis are lacking.48 
Myelofibrosis, terminologically referring to fibrosis in the bone marrow, presents a 
central entity within the different MPNs. Myelofibrosis can occur as a primary clinical 
manifestation (PMF), but both ET and PV can evolve into secondary myelofibrosis. 
Importantly, even though myelofibrosis is considered the ‘primary’ condition in PMF, 
biologically accurate myelofibrosis is a ‘secondary’ feature. Fibroblasts in PMF do 
not harbor driver mutations and are thus not considered malign cells.49 Similar to 
other fibrotic diseases, myelofibrosis in PMF is caused by cell-extrinsic effect of 
malign HSCs. Hence, there is a chronic activation of fibroblasts by growth factors 
deriving from the clonal cells. Clinically, however, both PMF and secondary 
myelofibrosis present common features. This study largely concentrates on PMF, 
nevertheless certain aspects are conferrable to myelofibrosis as a secondary 
condition. 
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PMF is a rare disease with 0.1 - 1 per 100,000 newly diagnosed cases per year in 
Europe.50 PMF, which is slightly more prevalent in men than in women, is typically 
diagnosed in elderly patients and median survival ranges from 1.8 years in high risk 
to 17.5 years in low risk patients.51 Disease symptoms are diverse and very 
heterogenic among patients, common features during PMF progression are 
summarized in Figure 1.2. Patients typically display symptoms of ineffective 
hematopoiesis such as anemia, thrombocythemia, evolving into thrombocytopenia in 
later stages, leukocytosis and increased numbers of circulating progenitor cells. 
Defects in blood cell maturation result in compensative extramedullary 
hematopoiesis in spleen and liver. Especially splenic hematopoiesis leads to an 
increase in size of the spleen, referred to as splenomegaly, which causes patients 
discomfort. Constitutional symptoms include bone pain, fatigue, cachexia and further 
unspecific symptoms. The bone marrow of PMF patients shows dysplastic 
megakaryocytes, neoangiogenesis, osteosclerosis and, as a central pathological 
feature, progressive fibrosis.52,53  
 
Figure 1.2: Clinical manifestation and pathological features of primary myelofibrosis (PMF) from a pre-fibrotic 
stage (pre-PMF) to overt PMF. LDH: lactate dehydrogenase, MF: myelofibrosis. Images for the illustration of 
MF grades (MF-0 to MF-3) are adopted and modified from Kvasnicka et al., 2016.54 
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Diagnosis of PMF is made according to the 2016 WHO revision on MPN classification 
and diagnostic criteria. These take into account clinical and laboratory features, such 
as blood cell counts and lactate dehydrogenase (LDH), but mainly rely on the 
assessment of bone marrow morphology.27 Bone marrow fibrosis is commonly 
visualized using a reticulum staining with WHO myelofibrosis (MF) scoring system 
ranging from grade MF-0 (normal condition) to grade MF-3 (dense and extensively 
intersectioned reticulum).54 The presence of driver mutations (JAK2, CALR and MPL) 
is supportive but not essential for diagnosis, since up to 10% of patients are triple-
negative for the three driver mutations. PMF is classified either as pre-fibrotic PMF 
or overtly fibrotic PMF. Especially in the pre-fibrotic stage, PMF is difficult to 
diagnose, since the morphological features and the lack of fibrosis in pre-PMF 
resemble features also commonly found in ET. However, it is highly relevant to 
correctly distinguish these two MPNs. ET and pre-fibrotic PMF are biologically 
different: megakaryocytes in PMF show peculiar dysplasia, an altered differentiation, 
and hence differences in pro-platelet production and cytokine storage within 
α-granules, whereas megakaryocytes in ET display hyperproliferation with excess 
platelet production.55,56 Also from a clinical point of view, prognosis and potential 
complications are very distinct in PMF and ET. In a cohort of 180 pre-PMF patients 
(formerly diagnosed with/classified as ET) and 891 ET patients, the 15-year survival 
for PMF and ET were 59% and 80%, respectively, and the 15-year leukemic 
transformation rates were 11.7% and 2.1%, respectively.57 Still, the histopathological 
assessment of diagnostic criteria such as megakaryocyte morphology, size, and 
clustering poses major problems for hematopathologists, and reproducibility is 
poor.58 The limitations in diagnostic precision and the lack of specific molecular 
markers for the respective MPNs emphasize the need for new diagnostic 
approaches. 
1.3.1 Molecular alterations in primary myelofibrosis 
1.3.1.1 JAK-STAT signaling 
Aberrantly activated janus kinase - signal transducer and activator of transcription 
(JAK-STAT) signaling is central to the pathogenesis of the classical, BCR-ABL-
negative MPNs and supports proliferation and differentiation of malign HSCs.59 In 
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approximately 90% of PMF patients, one of three main driver mutations can be 
detected (see Table 1.1).  
First described in 2005, the most common genetic aberration is a point mutation in 
janus kinase 2 (JAK2), which leads to substitution of a valine for a phenylalanine at 
position 617 (V617F) in the pseudokinase domain of JAK2.60 The pseudokinase 
domain exerts an inhibitory function that regulates the kinase activity,61 and mutation 
leads to a constitutive activation of JAK2.62,63  In 2013, CALR mutations were 
discovered in most PMF and ET patient who do not harbor JAK2 mutations.64 CALR 
encodes calreticulin, a chaperone in the endoplasmic reticulum (ER), which exerts a 
control function for unfolded proteins.65 Furthermore, calreticulin binds calcium ions 
and thus plays an important role in calcium-mediated intracellular signaling.66 
Importantly, CALR mutation promotes megakaryocytic differentiation, which is 
supportive of the fact that CALR mutations only occur in MPNs which affect the 
megakaryocytic lineage (ET and PMF).67 In recent years it has become more clear 
that CALR mutation leads to aberrant activation of JAK-STAT signaling as well, 
although mechanisms seem to be substantially different from JAK2V617F-mediated 
JAK-STAT activation.68 The thrombopoietin receptor MPL is required for mutant 
calreticulin to induce MPN,69,70 and CALR mutation leads to an increase in MPL 
expression.71 These data strongly indicate that CALR mutation leads to JAK-STAT 
activation downstream of MPL. In line with these data, mutations in MPL, which can 
be detected in 4-6% of ET and PMF patients, likewise lead to JAK-STAT activation.72 
Evidently, the main functional consequence of each of the three mutations is 
increased JAK-STAT signaling in HSCs. The fact that the mutations occur mutually 
exclusive further provides evidence for their capacity to independently activate JAK-
STAT signaling in disease-causing MPN stem cells. How exactly these alterations 
support the cell-extrinsic capacity of malign HSCs to promote myelofibrosis, 
however, is not yet known. 
1.3.1.2 Other mutations 
Although one of the three main driver mutations alone is sufficient to initiate disease 
in patients and in mouse models, they are accompanied by further acquired 
mutations in approximately 50% of MPN patients.73 Particularly as the disease 
progresses or leukemic transformation occurs, an accumulation of mutations can be 
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detected,74,75 indicating that additional genetic instability contributes to disease 
progression. Importantly, the specific mutational landscape has a strong negative 
impact on prognosis.37 Among the additional mutations, many genes are involved in 
RNA splicing (e.g. SRSF2 and U2AF1) and epigenetic regulation (e.g. ASXL1 and 
TET2).38 
1.3.1.3 Chronic inflammation and the bone marrow microenvironment 
The chronic inflammatory state of the bone marrow is considered a major 
pathophysiological component in myelofibrosis.76 During wound healing, 
inflammation is an important protective mechanism to promote tissue repair. Chronic 
inflammation, however, promotes fibrotic changes in organs.77 The increased 
expression of inflammatory cytokines in the bone marrow of PMF patients, among 
those, interleukin (IL)-2, IL-6, IL-8, tumor necrosis factor α and interferon γ, supports 
the hypothesis of chronic inflammation-driven bone marrow fibrosis.53,78 
Furthermore, transforming growth factor β (TGFβ), which is strongly associated with 
myelofibrosis, is crucial in tissue repair and inflammation.79 There are multiple 
mechanisms by which TGFβ exerts pro-fibrotic effects and promotes fibroblasts 
proliferation and extracellular matrix remodeling. For example, activation of TGFβ 
receptor leads to downstream extracellular signal-regulated kinase (ERK) and 
phosphatidylinositol 3-kinase (PI3K) signaling to promote proliferation of TGFβ 
receptor expressing cells.80,81 Furthermore, TGFβ induces expression of platelet-
derived growth factor (PDGF)-B82 and ErbB ligands.83 The hypothesis of a chronically 
inflamed bone marrow is also in line with the concept that myelofibrosis is caused by 
corrupted crosstalk between the defective microenvironment and HSCs, also referred 
to as the ‘bad seeds in bad soil’ concept.84,85 The importance of the complex cell-cell 
interactions within the bone marrow is further emphasized by the fact that normal 
megakaryocyte function is required for HSC quiescence.86 
1.3.1.4 Pro-fibrotic cytokines and growth factors 
The transformation from malign proliferation of hematopoietic cells to myelofibrosis 
seen in PMF has been ascribed to the overproduction of pro-fibrotic cytokines and 
growth factors by HSCs. PDGF signaling components have evolved as central 
mediators of myelofibrosis.87,88 Expression of the PDGF ligands, as well as PDGF 
receptor α (PDGFRα) and PDGF receptor β (PDGFRβ) expression is increased in 
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the bone marrow of PMF patients, regardless of driver mutations.89,90 Moreover, 
increased expression of basic fibroblast growth factor (bFGF),91 TGFβ,92,93 and 
vascular endothelial growth factors (VEGFs)94,95 can be detected, which promote 
fibroblast proliferation and neo-angiogenesis in the bone marrow. 
1.3.2 Current treatment options for primary myelofibrosis 
To date, allogeneic hematopoietic stem cell transplantation (HSCT) remains the only 
curative therapy for myelofibrosis. However, HSCT is associated with substantial 
morbidity and mortality, and is only suitable for a subset of PMF patients.96,97 All other 
therapies are palliative and are not able to improve or reverse bone marrow fibrosis. 
The discovery of JAK-STAT-associated mutations led to efforts in the development 
of JAK inhibitors. However, only one JAK inhibitor is approved by the US Food and 
Drug Administration (FDA) so far. Since its approval in 2011, the JAK1/2 inhibitor 
ruxolitinib (Jakavi®) has become part of combined standard therapy for PMF 
patients. Ruxolitinib treatment is not limited to patients harboring JAK2 mutations but 
shows equal efficacy in patients with other driver mutations.98,99 Long-term treatment 
with ruxolitinib reduces spleen size and prolongs the overall survival of PMF 
patients.100 However, there is no improvement or reversal of bone marrow fibrosis. 
Furthermore, efficacy of ruxolitinib is limited by drug resistances101 and JAK inhibition 
does not abrogate clonal proliferation.102 Moreover, studies show that ruxolitinib 
treatment does not suppress PDGF-AA and -BB production, and PDGFRα signaling 
remains active in splenocytes after ruxolitinib treatment in an MPN mouse model.103 
The most common symptomatic treatment strategies aim at rendering anemia 
(erythropoiesis-stimulating agents, androgens, immunomodulators, blood 
transfusions) and splenomegaly (ruxolitinib, hydroxyurea, radiation therapy, 
splenectomy).104 The limitations in efficient treatment of myelofibrosis clearly 
emphasizes the needs for new therapeutic approaches. 
 
1  INTRODUCTION  11 
 
1.4 PDGFs and their cognate receptors 
PDGFs and their cognate receptors have been identified as crucial mediators in bone 
marrow fibrosis. PDGFs are disulfide-bonded, dimeric proteins which were first 
described in 1974 for their ability to stimulate the growth of different cell types.105-107 
There are four PDGF isoforms, denoted PDGF-A, -B, -C and -D.108 PDGF-A and -B 
can either form homodimers (PDGF-AA and PDGF-BB) or heterodimers (PDGF-AB), 
which are processed intracellularly and then excreted as functional dimers.109-113 
PDGF-C and -D, which were first described in 2000 and 2001, are synthesized as 
homodimers (PDGF-CC and PDGF-DD). In contrast to the other PDGF dimers, 
PDGF-CC and -DD are released from cells as inactive precursors and are 
proteolytically cleaved by extracellular serine proteases.114,115 
PDGFs can bind two cognate receptors, PDGFRα and PDGFRβ, which have distinct 
ligand-binding specificities (Figure 1.3). PDGF-A binding is exclusive to the PDGFRα 
chain, but PDGF-B can bind both PDGFRα and PDGFRβ.116 Hence, depending on 
ligand dimers, PDGF receptors can form both homodimers and, if co-expressed, 
heterodimers. PDGF-CC can bind PDGFRα homo- and heterodimers,117 whereas 
PDGF-DD primarily binds PDGFRβ homodimers and, with lower affinity, receptor 
heterodimers.114,116 Depending on co-expression, ligands can act on their receptors 
in a paracrine or an autocrine manner.118 
 
Figure 1.3: Schematic illustration of platelet-derived growth factor (PDGF) isoforms and binding specificities of 
the ligand dimers towards transmembranous PDGF receptor (PDGFR) α and β homo- and heterodimers. [*] 
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PDGF-A is mainly expressed in epithelial, myogenic, and neuronal progenitor cells. 
PDGF-B expression can also be detected in endothelial and neuronal cells, enabling 
heterodimerization with PDGF-A. The largest share of PDGF-B, however, derives 
from megakaryocytes, where PDGF-B is stored in the growth factor-storing granules 
of platelets, referred to as α-granules. PDGF-C expression overlaps with PDGF-A 
expression, and PDGF-D can be detected in fibroblasts and smooth muscle cells, 
possibly acting on PDGFRβ in an autocrine manner.116,119 PDGF receptors are 
predominantly expressed by cells of mesenchymal origin. Within the bone marrow, 
PDGFRα is expressed in endosteal and endothelial cells, but highest expression is 
observed in megakaryocytes.89 PDGFRβ, in contrast, is almost exclusively 
expressed in fibroblasts, but can also be detected in vascular smooth muscle cells 
and pericytes.90,116 
The PDGF system plays a crucial role in embryonal development, as highlighted by 
several mouse studies. PDGF-B and PDGFRβ knockout is perinatally lethal, and 
mice show severe cardiovascular, renal and hematopoietical deficiencies.120-122 Mice 
lacking PDGF-A die either pre- or postnatally showing alveolar septation defects,123 
and PDGFRα knockout mice die during embryonic development displaying 
incomplete cephalic closure.124 Knockout of PDGF-C is perinatally lethal and mice 
display respiratory defects,125 whereas PDGF-D knockout mice are viable with a mild 
vascular phenotype.126 
1.4.1 PDGF receptor structure and signaling 
PDGF receptors are transmembrane receptor tyrosine kinases (RTKs) which have 
an extracellular part, consisting of five Immunoglobulin (Ig)-like domains that contain 
the ligand binding site (see Figure 1.4, exemplary for PDGFRβ structure). Receptors 
are further constituted of a transmembrane domain, followed by a juxtamembrane 
domain, an intracellular tyrosine kinase domain and a C-terminal tail.127 Upon PDGF-
binding, receptors dimerize and cross-phosphorylate intracellular tyrosine residues, 
which serve as binding sites for downstream signaling components.128 
The major share of PDGFRβ tyrosine phosphorylation sites are located near the 
intracellular protein kinase domain of the receptor (Figure 1.4) and phosphorylated 
by autocatalysis, however, some tyrosine sites can be phosphorylated by ABL non-
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receptor tyrosine kinases129 or Src.130 The receptor contains an activation loop 
including the Y857 phosphorylation site, hence autophosphorylation at Y857 is 
necessary for full activation of PDGFRβ.131 Most other phosphorylated tyrosine 
residues provide docking sites for Src homology 2 (SH2) domain containing adapter 
proteins, such as Src and Grb2.132 Since these proteins have distinct preferences in 
amino acid sequence adjacent to the phosphotyrosine binding site, the different 
PDGFRβ tyrosine phosphorylation sites are bound by specific proteins. Two 
autophosphorylation sites in the juxtamembrane region (Y579 and Y581) mediate 
binding to Src.133 The Y740 and Y751 sites are required for PI3K activation, which is 
bound to PDGFRβ via its p85 subunit,134,135 and hence phosphorylation at Y751 is 
necessary for downstream AKT activation.136 Phosphorylated Y716 and Y775 sites 
mediate binding to Grb2 and activate downstream ERK signaling.137,138 
Phosphorylation at Y771 serves as a binding site for GTPase activating protein of Ras 
(RasGAP), counteracting the activation of ERK signaling.135,139,140 While PDGFRα 
and PDGFRβ largely share common signaling mechanisms, PDGFRα-induced ERK 
signaling is not regulated by RasGAP-binding.141 Phosphorylation at sites Y1009 and 
Y1021 activates phospholipase C γ1 (PLCγ1) and protein lipase C-mediated calcium 
signaling.142,143 Together, the activated pathways promote proliferation, survival, 
migration and differentiation of cells.128 
The kinase domain sequences of human PDGFRα and PDGFRβ share 65% amino 
acid sequence homology. The C-terminal tail, in contrast, only displays 32% 
homology (sequences collected from UniProt database and aligned using NCBI 
blastp® tool), and hence, differences in PLCγ1 activation intensity have been 
observed.144 Nevertheless, both receptors activate the same signaling pathways. 
Differences in function of the two receptors have mainly been attributed to different 
PDGFR expression patterns in cells and tissues. The question whether there are 
different signaling mechanisms of the receptor isoforms has been addressed by 
replacing the intracellular domain of PDGFRα with the PDGFRβ intracellular domain, 
and vice versa. These experiments revealed a large functional overlap, demonstrated 
by a substantial rescue, although fusion with the intracellular PDGFRα domain did 
not rescue PDGFRβ without vascular defects.145 This indicates physiologically 
relevant differences in α and β receptor signaling in normal tissue development. 
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Figure 1.4: Schematic illustration of platelet-derived growth factor receptor β (PDGFRβ) structure, tyrosine 
phosphorylation sites and activated signaling pathways. Ig-like: immunoglobulin-like domain, 
PI3K: phosphatidylinositol 3-kinase, PLCγ1: phospholipase C γ1, RasGAP: GTPase activating protein of Ras. [*] 
1.4.2 The PDGF system in proliferative diseases, cancer and fibrosis 
The PDGF system has been implicated in various proliferative diseases and tissue 
remodeling processes, e.g. pulmonary arterial hypertension146,147 and neointima 
formation.148,149 Further, dysregulation of PDGF signaling is involved in different 
types of cancer, as summarized in Table 1.2. For example, mutations in PDGFRα 
can be detected in 5-10% of glioblastoma patients150-152 and in 5% of patients with 
gastrointestinal stromal tumors.153 PDGF receptor fusion proteins are associated with 
certain types of leukemia154,155 and in dermatofibrosarcoma protuberans, a rare skin 
cancer, expression of a collagen 1A1‒PDGF-B fusion protein is evident in 100% of 
patients.156,157 Further, PDGF signaling components are often differentially 
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expressed, e.g. in many types of breast, brain, liver, lung and prostate cancer. Often, 
but not always,158 increased PDGF receptor expression negatively correlates with 
prognosis.159-161 
 
Table 1.2: Implication of platelet-derived growth factor (PDGF) ligands and receptors in proliferative diseases 
and cancer. CML: chronic myeloid leukemia, PMF: primary myelofibrosis. 
Proliferative disease/cancer type Mutation/consequence 
Artery intimal sarcomas PDGFRα (overexpression)162 
Breast cancer PDGFRα (overexpression)159 
CML with hypereosinophilia FIP1L1-PDGFRα fusion protein155 
Chronic myelomonocytic leukemia TEL-PDGFRβ fusion protein154 
Dermatofibrosarcoma protuberans 
COL1A1-PDGF-B translocation,               
overexpression156,157 
Esophageal squamous cell 
carcinoma 
PDGFRα (overexpression)163 
Gastrointestinal stromal tumors PDGFRα (activating mutation D842V)153 
Glioblastoma 
PDGFRα (exon 8, 9 deletion,                       
overexpression)150-152 
Hepatocellular carcinoma 
PDGF-A, PDGFRα, PDGFRβ                       
(overexpression)164 
Non-small cell lung cancer 
PDGF-A (overexpression), PDGFRα            
(mutation, overexpression)160,165 
Oligodendrogliomas PDGFRα (overexpression)166,167 
PMF 
PDGF-A, PDGF-B, PDGFRα, PDGFRβ                         
(overexpression)89,90 
Prostate cancer PDGF-D, PDGFRβ (overexpression)168,169 
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In addition to the clear implication of PDGF signaling components in clonal cells, they 
often play a crucial role in the tumor microenvironment. Malign cells largely depend 
on the tumor stroma, hence fibroblasts, pericytes and other stromal cells support 
tumorgenesis.170,171 Whereas cancer cells often aberrantly express PDGFRα, stromal 
cells in the tumor microenvironment are frequently associated with PDGFRβ 
expression.172,173 Importantly, the PDGF signaling components also have a strong 
implication in organ fibrosis. Fibrosis is characterized by fibroblast proliferation in 
response to cytokines and growth factors and the production of ECM components. 
As PDGFs and their receptors mediate proliferation of mesenchymal cells, it seems 
conclusive that the PDGF system has evolved as a central mediator of organ fibrosis. 
For example, PDGF-A, -B and PDGFRα expression is induced in lung fibrosis.174-176 
In liver fibrosis, PDGFRβ plays a pivotal role, with simultaneous increase in PDGF-A, 
-B and -D expression.177-179 Further, PDGF-B is highly induced in renal fibrosis180,181 
and scleroderma.182,183 Additionally, PDGFRβ activation by PDGF-DD has been 
attributed an important role in renal fibrosis.184 Similar observations can be found in 
most types of organ fibrosis.185,186 Myelofibrosis, classified as a proliferative disease 
(HSCs) and therefore listed in Table 1.2, but with fibrosis as a central feature, is 
likewise driven by induced expression of PDGF components. Expression of PDGF-A 
and -B, as well as expression of the two receptors, is increased in the bone marrow 
of PMF patients.89 Importantly, PDGFRβ expression in PMF is almost exclusively 
detected in bone marrow fibroblasts, and expression in activated fibroblasts 
correlates with the grade of myelofibrosis.90 Further studies suggest that PDGFRβ 
expression is enhanced in early stages of bone marrow fibrosis and that increased 
PDGFRβ expression precedes fiber accumulation. Conclusively, 
immunohistochemical staining of PDGFRβ in bone marrow of PMF patients has been 
suggested as a marker for PMF progression.90,187,188 
1.4.3 Therapeutic targeting of PDGF signaling components  
Due to their implication in various cancers, tumor microenvironment and fibrosis, 
PDGFs and their receptors have increasingly gained interest as therapeutic targets. 
Several kinase inhibitors are applicable as PDGF receptor antagonists, e.g. 
cediranib, nilotinib, imatinib, pazopanib, sorafenib and sunitinib.189 Especially 
imatinib, a tyrosine kinase inhibitor which inhibits the BCR-ABL fusion protein and is 
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commonly used for CML treatment,190 has substantial relevance in context of MPNs 
and myelofibrosis. In CML patients with hypereosinophilia expressing the FIP1L1-
PDGFRα fusion protein, as well as in patients with chronic myelomonocytic leukemia 
expressing the TEL-PDGFRβ fusion protein, imatinib treatment showed clinical 
efficacy and disease remission.191,192 There have been different reports on imatinib 
treatment in patients with myelofibrosis: in one study including 23 patients, imatinib 
caused side effects without remarkable benefits for patients;193 a second study with 
11 patients reported a similar outcome;194 in a third study including 18 patients, 
responses were positive but marginal.195 However, none of these studies included 
PDGFRβ expression analyses in the bone marrow of patients. Hence, PDGF 
targeting treatment or kinase inhibition could potentially be more efficient in patients 
who have been screened for PDGF receptor expression or activation status. 
A number of patients might respond to and benefit from treatment, nevertheless, 
appropriate in situ methods to detect the receptor activation status for diagnostics 
are not yet established. 
Most tyrosine kinases inhibitors function by blocking the ATP-binding site of RTKs, 
and hence lack specificity. None of the inhibitors mentioned above is specific for one 
PDGF receptor, but inhibit both PDGFRα and PDGFRβ. Furthermore, these inhibitors 
do not only target PDGF receptor but have other primary targets such as ABL, VEGF 
receptors or Kit.189 To overcome the limitations caused by the lack of specificity, other 
approaches aim at blocking PDGF-binding to the receptors. Monoclonal antibodies 
or antibody fragments targeting the ligands or receptors are being evaluated.196-198 
One example is the PDGFRα-targeting monoclonal antibody olaratumab, which 
prolongs survival in soft tissue sarcoma patients when administered in combination 
with the chemotherapeutic agent doxorubicin.198 Furthermore, a vaccine prepared 
from PDGF‑B polypeptides coupled to carrier proteins was investigated for the 
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1.5 Protein tyrosine phosphatases 
Different mechanisms are involved in the regulation of PDGF signaling, e.g. injury 
and pro-inflammatory cytokines affect expression of the ligands and receptors.185 
Similar to most transmembrane RTKs, PDGF receptors are internalized upon ligand 
binding and either recycled to the cell surface, or ubiquitinated and degraded.200 
Nevertheless, ligand-induced endocytosis is not solely a negative regulation, since 
receptor signaling continues after internalization, and endocytosis is required for full 
activation of downstream signaling pathways.201,202 The most relevant regulatory 
components for PDGF receptors are protein tyrosine phosphatases (PTPs), which 
dephosphorylate intracellular tyrosine residues and are thus regulatory modulators 
of RTKs.203,204 
Virtually every signaling event within and between cells relies on phosphorylation of 
proteins and hence, phosphorylation is of paramount importance for transcriptional 
and translational processes, cell proliferation, migration and differentiation.205 To 
date, 107 genes coding for PTPs have been identified and therefore outnumber the 
90 RTKs encoded within the human genome.206,207 PTPs are very selective in 
substrate specificity and require defined amino acid sequences for their catalytic 
activity.208 However, most PTPs dephosphorylate more than only one RTK. 
Conclusively, PTPs are equally important for the cellular phosphorylation status, 
compared to RTKs.209 The 107 PTPs are structurally divided into four groups: class I 
PTPs (38 classical PTPs and 61 dual-specific phosphatases), class II PTPs (low 
molecular weight (LMW)-PTP, one member), class III PTPs (CDC25 phosphatases, 
three members) and class IV PTPs (EYA, four members).210 Based on their location, 
the 38 classical PTPs are further classified as transmembranous, receptor-like PTPs 
(PTPRs, 21 members) and cytosolic, non-receptor PTPs (PTPNs, 17 members).207 
In addition to cell-type specific expression, the structural diversity of PTPRs and 
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Figure 1.5: Structural diversity of class I classical protein tyrosine phosphatases (PTPs), subgrouped as non-
receptor PTPs (PTPNs) and receptor-like PTPs (PTPRs). BRO1: BRO1 homology, CAH: carbonic anhydrase-
like, Cad: cadherin-like juxtamembrane sequence, FERM: FERM mephrin/A5/μ domain, FN: fibronectin type III-
like domain, Gly: glycosylated, HD: histidin domain, Ig: immunoglobulin domain, KIM: kinase-interacting motif, 
MAM: mephrin/A5/μ domain, Pro: proline-rich, RGDS: RGDS-adhesion recognition motif, 
SEC14: SEC14/cellular retinalaldehyde-binding protein-like, SH2: Src homology 2. Adopted and modified from 
Tonks, 2006.207,[*] 
Several PTPs have been identified as PDGFRβ-targeting enzymes (Table 1.3). 
Among these, six PTPs belong to the class I classical PTP-subgroup (five cytosolic 
PTPNs and one transmembranous PTPR). PTEN is a dual-specific phosphatase, 
which, in addition to tyrosine residues, dephosphorylates serine and threonine 
residues. Furthermore, the class II LMW-PTP has been identified to dephosphorylate 
PDGFRβ. 
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Table 1.3: Platelet-derived growth factor receptor β (PDGFRβ)-targeting protein tyrosine phosphatases (PTPs) 
and targeted tyrosine phosphorylation sites. 
Gene Protein PDGFRβ tyrosine phosphorylation site References 
PTPN1 PTP1B Y716, Y751  118,211-213 
PTPN2 TC-PTP preferably Y1021 and Y771  212,214 
PTPN6 SHP-1 n/a 215,216 
PTPN11 SHP-2 Y751, Y740, Y763, Y771, Y1009, Y1021 212,217-221 
PTPN12 PTP-PEST Y1021  212,222 
PTPRJ DEP-1 preferably Y1021  148,223 
PTEN PTEN n/a 224 
ACP1 LMW-PTP Y857 225 
 
Most of these PTPs negatively regulate PDGFRβ, nevertheless, SHP-2 is a PTP 
which has been ascribed positive effects on signaling.220,221 For instance, SHP-2 
serves as an adapter protein for Grb2 and thus promotes ERK signaling.226 
Reversely, not all phosphorylation sites are associated with receptor activation. 
Phosphorylation on serine residues, for example, inhibit the tyrosine kinase activity 
of PDGFRβ.227 Thus, the PDGFRβ phosphorylation and activation status is refined 
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1.6 Aim of the study 
PMF is a fatal disease with perspicuous limitations in early diagnosis and a scarcity 
in adequate treatment options. PDGFs and their receptors are linked to myelofibrosis 
based on their increased expression in the bone marrow of PMF patients.89,90 
However, the mechanisms of transformation from malign clonal proliferation of HSCs 
to myelofibrosis and the involvement of the PDGF system are not fully understood. 
Especially the time-dependent expression dynamics of PDGF receptors, the 
interaction with the PDGF ligands, and the regulation by PTPs during the 
development of bone marrow fibrosis have not been thoroughly addressed. Using a 
mouse model for PMF, this study therefore concentrated on PDGFRβ and its 
relevance in fibroblast proliferation.  
In particular, this study aimed at: 
(1) Analyzing the expression dynamics and localization of PDGF signaling 
components during PMF development 
(2) Comprehensively evaluating the PDGFRβ activation status in bone marrow 
fibrosis by analyzing receptor-ligand interaction and receptor phosphorylation 
using a novel in situ proximity ligation assay (PLA) 
(3) Evaluating PLA as a novel diagnostic method in the bone marrow 
(4) Assessing the expression of PTPs and evaluating the regulation of PDGFRβ by 
PTPs during PMF development  
(5) Investigating the regulation of PDGFRβ by candidate PTPs in fibroblasts in vitro 
 
For a detailed characterization in the time-dependent development of PMF in mice, 
the bone marrow of Gata-1low mice was assessed in a pre-, an early and an overt 
fibrotic stage to create in-depth analyses of expression, activation and regulation of 
PDGFRβ during the development of bone marrow fibrosis. 
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2 MATERIALS AND METHODS 
2.1 Materials 
2.1.1 Equipment 
Agarose gel electrophoresis equipment Baacklab 
Analytical balance (SE 523i) VWR 
Centrifuge for conical tubes (Universal 32 R) Hettich 
Centrifuge for multiwell plates (5810 R) Eppendorf 
CO2 incubator (HeraCell 150) Heraeus 
Cooling plate for histology (EG1130) Leica 
Epifluorescence microscope (BZ-9000)  Keyence 
Film processor (Curix 60) AGFA 
Heating block (ThermoMixer®)  Eppendorf 
Hematology analyzer (K4500) Sysmex 
Histology staining jars Fisher Scientific 
Incubator (BE 400) Memmert 
Laminar flow hood (LaminAir 1.2) Heto-Holten 
Live cell imaging system (IncuCyte®) Essen Bioscience 
Magnetic stirrer (RET basic)  IKA 
Microcentrifuge (PerfectSpin) Peqlab 
Micropipettes (Pipet-Lite XLS, 2, 10, 100, 200, 1000 µl) Rainin 
Microscope (DM IL) Leica 
Microtome (HM 325 rotary microtome) Thermo Scientific 
Microwave (Continent MW800) GGV 
Mixing device (Vortex Genie 2)  Scientific Industries 
Multispectral Imager (Vectra® Polaris™) Perkin Elmer 
PCR cycler (PTC-100™) MJ Research 
pH meter (accumet® AE150)  Fisher Scientific 
Pipette controller (accu-jet® pro) Brand 
Platform shaker (PMR-30) Grant Instruments 
Protein gel electrophoresis equipment Bio-Rad 
Real time PCR cycler (Mx3000P)  Stratagene 
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Spectrophotometer (NanoDrop® ND-1000)  Peqlab 
Tissue embedding station (EC 350-1)  Thermo Scientific 
Tissue processor (Shandon Citadel 1000) Thermo Scientific 
Waterbath, floating, for histology Enno Vieth 
Waterbath for cell culture Memmert 
2.1.2 Consumables 
Barrier pen, hydrophobic (PAP pen) Daido Sangyo 
Blood collection needles (S-Monovette®, 20Gx1”) Sarstedt 
Blood collection tubes (S-Monovette®, 1.2 ml, EDTA) Sarstedt 
Blotting paper Bio-Rad Laboratories 
Cell culture flasks (75 cm2, Falcon®) Corning 
Cell scraper (Costar®) Corning 
Chamber slides (Lab-Tek®II) Thermo Fisher Scientific 
Chemiluminescence detection films (Hyperfilm ECL)  Amersham, GE Healthcare 
Coverslips (24x40 mm, 24x60 mm, Menzel™) Fisher Scientific 
Microscope slides (SuperFrost®Plus)  VWR 
Microtome blades (A35) FEATHER Safety Razor 
Multiwell plates (6, 96 well, Falcon®) Corning 
Pipet tips (10, 200, 1000 µl) Sarstedt 
Pipets, serological (5, 10, 25, 50 ml, Falcon®) Corning 
Polyvinylidene difluoride (PVDF) blotting                     
membrane (Amersham Hybond™-P) 
GE Healthcare 
qPCR plates (96 well) Sarstedt 
qPCR plate sealing tape Sarstedt 
Reaction tubes (0.2 ml) for PCR Sarstedt 
Reaction tubes (1.5, 2 ml, SafeSeal) Sarstedt 
Reaction tubes, conical (15, 50 ml, Falcon®) Corning 
Scalpels FEATHER Safety Razor 
Tissue cassettes Simport 
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2.1.3 Chemicals, reagents and solvents 
Acetic acid J.T.Baker 
Acrylamide/bis solution (30%) Serva 
Agarose Serva 
Ammonium persulfate (APS) VWR 
Autofluorescence inhibitor reagent Merck 
β-Mercaptoethanol AppliChem 
Bovine serum albumin (BSA), blotting grade AppliChem 
Bradford dye reagent Bio-Rad Laboratories 
Bromphenol blue sodium salt Merck 
Chemiluminescence detection reagent (Amersham™) GE Healthcare 
Chloroform J.T.Baker 
Deoxycholic acid sodium salt Serva 
Developer and fixation solution (G153 and G354) Agfa 
4′,6-Diamidino-2-phenylindole dihydrochloride (DAPI) Perkin Elmer 
DNA ladder (GeneRuler™, 100 bp) Thermo Fisher Scientific 
Ethanol (EtOH) ≥ 99.8%, 96%, 70% Roth 
Ethidium bromide solution (1%) Roth 
Ethylenediaminetetraacetic acid (EDTA) Sigma-Aldrich 
Glycerol Sigma-Aldrich 
Glycine Roth 
Hydrochloric acid (HCl, 32%) Labochem international 
Isopropanol Merck 
Milk, powdered, blotting grade Roth 
Mounting medium, anhydrous (Neo-Mount®) Merck 
Mounting medium (ProLong™ Diamond Antifade) Thermo Fisher Scientific 
Mounting medium with DAPI (Fluoroshield™) Abcam 
Methanol Merck 
Neo-Clear® (xylene substitute) Merck 
Paraffin type 6 Thermo Scientific 
Paraffin type 9 Thermo Scientific 
Phosphatase inhibitor tablets (PhosSTOP™) Roche 
Phosphate-buffered formaldehyde (4%) Labochem international 
Protease inhibitor tablets (cOmplete™ Mini) Roche 
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Protein ladder (PageRuler™, prestained) Thermo Fisher Scientific 
Sodium chloride (NaCl) Merck 
Sodium dodecyl sulfate (SDS) Roth 
Sodium hydroxide (NaOH) VWR 
Sodium pyrophosphate Sigma-Aldrich 
Tetramethylethylenediamine (TEMED) Roth 
TRI reagent® Sigma-Aldrich 
Tris Roth 
Tris-HCl Roth 
Trisodium citrate dihydrate Merck 
Triton™ X-100 Sigma-Aldrich 
Tween® 20 Serva 
2.1.4 Enzymes and kits 
GoTaq® G2 DNA polymerase, buffer and deoxy-                 
nucleotide triphosphates (dNTPs) 
Promega 
High Capacity RNA-to-cDNA Kit Applied Biosystems 
Duolink® in situ Detection Reagents Orange Sigma-Aldrich 
SYBR® Green PCR Master Mix Applied Biosystems 
2.1.5 Buffers and solutions 
Water quality is essential for many experimental procedures and different water 
purity grades were used in this study. Water purity grades are indicated as follows: 
Tab water - tab water 
H2O  - distilled water 
pure H2O - low endotoxin, DNase- and RNase-free water (Biochrom) 
 
Antigen Retrieval buffer 10 mM Sodium citrate 
0.05% (v/v) Tween® 20 
in H2O, pH 6 
 
APS stock solution 10% (w/v) APS 
in pure H2O 
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Decalcification solution 10% (w/v) EDTA 
in H2O, pH 7.4 
 
DNA extraction solution I 25 mM NaOH 
0.2 mM EDTA 
in pure H2O 
 
DNA extraction solution II 40 mM Tris-HCl 
in pure H2O, pH 5.5 
 
Lysis buffer 150 mM NaCl 
20 mM Tris 
10 mM EDTA 
7.5 mM Sodium pyrophosphate 
0.5% (w/v) Deoxycholic acid 
0.5% (v/v) Triton™ X-100 
in pure H2O, pH 7.5 
 
Protein loading buffer (6x) 350 mM Tris-HCl 
10% (w/v) SDS 
36% (w/v) Glycerol 
5% (v/v) β-Mercaptoethanol 
0.025% (w/v) Bromphenol blue 
in pure H2O, pH 6.8 
 
SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE) buffer 
25 mM Tris 
192 mM Glycine 
0.05% (w/v) SDS 
in H2O 
 
SDS stock solution 10% (w/v) SDS in pure H2O 
 
Separation gel buffer 1.5 M Tris-HCl 
in H2O, pH 8.8 
 
Stacking gel buffer 0.5 M Tris-HCl 
in H2O, pH 6.8 
 
Stripping buffer 200 mM Glycine 
0.1% (w/v) SDS 
1% (v/v) Tween® 20 
in H2O, pH 2.2 
 
Transfer buffer 25 mM Tris 
192 mM Glycine 
0.05% (w/v) SDS 
20% (v/v) Methanol 
in H2O 
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Tris-Acetate-EDTA (TAE) buffer 40 mM Tris 
20 mM Acetic acid 
1 mM EDTA 
in H2O, pH 8.4 
 
Tris-buffered saline with Tween® 20  
(TBS-T) 
150 mM NaCl 
20 mM Tris 
0.1% (v/v) Tween® 20 
in H2O, pH 7.4 
 
Wash buffer 100 mM NaCl 
200 mM Tris 
in H2O, pH 7.5 
2.1.6 Staining solutions, dyes and kits 
Giemsa staining solution Dr. K. Hollborn & Söhne 
May-Grünwald staining solution Dr. K. Hollborn & Söhne 
Reticulum Stain Kit Abcam 
Opal™ fluorophores PerkinElmer 
2.1.7 Primers 
All primers used for this study were purchased from Invitrogen (Thermo Fisher 
Scientific), diluted with pure H2O to obtain a 10 µM concentration and stored at -20°C. 
Primer sequences for mouse genotyping by polymerase chain reaction (PCR) 
originate from the Jackson Laboratory standard protocol: 
Gata-1low forward 5’–GACCCATCCATCTCCTTTCC–3’ 
Gata-1low reverse 5’–GTGTGAGAGTGGCTATGTGC–3’ 
Wild type forward 5’–ACTCTTGCTCTCTTTTGCAG–3’ 
Wild type reverse 5’–AATCAGGAATGCAACATCTC–3’ 
 
All primers used for quantitative polymerase chain reaction (qPCR) analyses were 
designed to be specific to the target gene in the mouse genome using Primer-BLAST 
tool.228 If applicable for the individual gene structure, amplicons span at least one 
intron to avoid amplification in genomic DNA. Primer sequences used for qPCR are 
listed below. 
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Col1a1 forward 5’–CTGACGCATGGCCAAGAAGA–3’ 
Col1a1 reverse 5’–ATACCTCGGGTTTCCACGTC–3’ 
Col3a1 forward 5’–CTGGTCCTGCTGGAAAGGAT–3’ 
Col3a1 reverse 5’–TCCATTGCGTCCATCAAAGC–3’ 
Pdgfa forward 5’–TTGTAACACCAGCAGCGTCA–3’ 
Pdgfa reverse 5’–CTCCACTTTGGCCACCTTGA–3’ 
Pdgfb forward 5’–CGGCCTGTGACTAGAAGTCC–3’ 
Pdgfb reverse 5’–GAGCTTGAGGCGTCTTGG–3’ 
Pdgfra forward 5’–AGTGGCTACATCATCCCCCT–3’ 
Pdgfra reverse 5’–CCGAAGTCTGTGAGCTGTGT–3’ 
Pdgfrb forward 5’–ACGGCATGGACTTCTTAGCC–3’ 
Pdgfrb reverse 5’–ATCTTGACCAGCTTGCCCTC–3’ 
Ptpn1 forward 5’–CGGGAGGTCAGGGACCTT–3’ 
Ptpn1 reverse 5’–GGGTCTTTCCTCTTGTCCATCA–3’ 
Ptpn2 forward 5’–GCTACGACGGCTCAGAAGGT–3’ 
Ptpn2 reverse 5’–TGTCTGTCAATCTTGGCCTTTTT–3’ 
Ptpn6 forward 5’–CGTACCCTCCCGCTGTGA–3’ 
Ptpn6 reverse 5’–TTTTCGTACACCTCCTCCTTGTG–3’ 
Ptpn11 forward 5’–CCTCAACACAACTCGTATCAATGC–3’ 
Ptpn11 reverse 5’–TGTTGCTGGAGCGTCTCAAA–3’ 
Ptpn12 forward 5’–GAGTCGCCTCCTCCTTTACC–3’ 
Ptpn12 reverse 5’–TGGAAGTTCATGCCACTCAGG–3’ 
Ptprj forward 5’–GCAGTGTTTGGATGTATCTTTGGT–3’ 
Ptprj reverse 5’–CTTCATTATTCTTGGCATCTGTCCTT–3’ 
Hprt forward 5’–TGCTGACCTGCTGGATTACA–3’ 
Hprt reverse 5’–TATGTCCCCCGTTGACTGAT–3’ 
2.1.8 Antibodies and antibody-conjugates 
All antibody-based approaches in this study were preceded by blocking of non-
specific binding sites. Different blocking reagents were used for the following 
applications: 
Multiplexed immunohistochemistry: Serum-free protein block solution (Dako) 
PLA and immunofluorescence:  Duolink® blocking solution (Sigma-Aldrich) 
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Immunoblotting:    3% milk in TBS-T for pPDGFRβ Y751 
5% BSA in TBS-T for all other antibodies 
All primary antibodies used for this study are listed in Table 2.1 below. A list of 
secondary antibodies and antibody-conjugates is summarized in Table 2.2. 
Table 2.1: Primary antibodies used in this study, including species/clonality, catalog#, supplier and dilutions for 
the respective applications. IB: Immunoblot, IF: immunofluorescence, Ig: immunoglobulin, mIHC: multiplexed 







Akt Rabbit pAb 9272 Cell Signaling Technology IB: 1:1000 
pAkt S473 Rabbit mAb 4060 Cell Signaling Technology IB: 1:2000 
β-Actin Mouse mAb sc-81178 Santa Cruz IB: 1:500 
Erk1/2 Rabbit pAb 9102 Cell Signaling Technology IB: 1:1000 
pErk1/2 T204/Y204 Rabbit mAb 4370 Cell Signaling Technology IB: 1:2000 
GAPDH Mouse mAb MAB374 Millipore IB: 1:50000 
Pan-pY pY100 Mouse mAb 9411 Cell Signaling Technology PLA: 1:500 
Pan-pY pY20 Mouse mAb ab10321 Abcam PLA: 1:900 
Pan-pY 4G10 Mouse mAb 05-321 Merck Millipore PLA: 1:1000 
PDGFRα D1E1E  Rabbit mAb 3174 Cell Signaling Technology 
mIHC: 1:80 
PLA: 100 
PDGFRβ 28E1 Rabbit mAb 3169 Cell Signaling Technology IB: 1:1000 
PDGFRβ 42G12 Mouse mAb NBP1-19191 Novus Biologicals PLA: 1:50 
PDGFRβ Y92  Rabbit mAb ab32570 Abcam 
mIHC: 1:50 
PLA: 1:50 
pPDGFRβ Y751 Mouse mAb 3166 Cell Signaling Technology IB: 1:1000 
pPDGFRβ Y1021 Rabbit pAb ab16868 Abcam IB: 1:2000 
PDGF-A  Mouse mAb sc-9974 Santa Cruz 
mIHC: 1:50 
PLA: 1:50 
PDGF-B  Rabbit pAb ab21234 Abcam 
mIHC: 1:80 
PLA: 1:50 
PLCγ1 Rabbit pAb #2822 Cell Signaling Technology IB: 1:1000 
pPLCγ1 Y783 Rabbit pAb #2821 Cell Signaling Technology IB: 1:1000 








X0903 Dako PLA: 1:10000 
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Table 2.2: Secondary antibodies and secondary antibody-conjugates used in this study, including 
species/clonality, catalog#, supplier and dilutions for the respective applications . IB: Immunoblot, 
IF: immunofluorescence, HRP: horseradish peroxidase, mIHC: multiplexed immunohistochemistry, 







Anti-mouse-Alexa Fluor 568 Goat pAb A11004 Thermo Fisher Scientific IF: 1:1000 
Anti-rabbit-Alexa Fluor 488 Goat pAb A11008 Thermo Fisher Scientific IF: 1:500 
Anti-mouse-HRP Rabbit pAb P0260 Dako IB: 1:2000 
Anti-rabbit-HRP Swine pAb P0217 Dako IB: 1:1000 
ImmPRESS® anti-mouse-HRP Horse IgG MP-7402 Vector Laboratories mIHC: ready-to-use 
ImmPRESS® anti-rabbit-HRP Horse IgG MP-7401 Vector Laboratories mIHC: ready-to-use 
Duolink® in situ PLA probe anti-
mouse PLUS 
Donkey IgG DUO92001 Sigma Aldrich PLA: 1:5 
Duolink® in situ PLA probe anti-
mouse MINUS 
Donkey IgG DUO92004 Sigma Aldrich PLA: 1:5 
Duolink® in situ PLA probe anti-
rabbit PLUS 
Donkey IgG DUO92002 Sigma Aldrich PLA: 1:5 
Duolink® in situ PLA probe anti-
rabbit MINUS 
Donkey IgG DUO92005 Sigma Aldrich PLA: 1:5 
2.1.9 Mice 
Gata-1low mice were purchased from Jackson Laboratory (Bar Harbour, ME, USA).  
2.1.10 Cell line, cell culture, transfection and stimulation materials 
NIH-3T3 fibroblasts were purchased from American Type Culture Collection 
(ATCC®). All cell culture reagents were sterile, suitable for use in cell culture and 
handled aseptically under laminar air flow. 
Dulbecco‘s modified eagle medium (DMEM) 
4.5g/L D-glucose, L-glutamine, 110 mg/L sodium pyruvate 
Gibco 
Fetal bovine serum (FBS) Gibco, Lot: 0861360K 
Lipofectamine™ 2000 Invitrogen 
Opti-MEM® reduced serum medium Gibco  
Dulbecco‘s phosphate buffered saline (PBS) Gibco 
PDGF-BB, human recombinant Peprotech 
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Penicillin/streptomycin  Merck 
siRNA, nontargeting (NT) control no. 1 (Ambion®) Thermo Fisher Scientific 
siRNA, mouse Ptpn2 (Ambion®, id 150390) Thermo Fisher Scientific 
Trypsin/EDTA solution Merck 
2.1.11 Software and online tools 
Table 2.3: Software, version, developer and application used in this study. mIHC: multiplexed 
immunohistochemistry, PLA: proximity ligation assay, qPCR: quantitative polymerase chain reaction. 
Software Version Developer Application 
BLASTP  2.9.0+ 





Duolink® ImageTool 1.0.1.2 Sigma-Aldrich 
Quantification of 
PLA signals 









of RNA sequencing 
data 








filter for PLA signals 
IncuCyte® 2018A 20181.2.0.0 Essen Bioscience 
Live cell imaging of 
NIH-3T3 cells 













MxPro Mx3000P 4.10 Stratagene qPCR analyses 





National Center for 
Biotechnology 
Information (NCBI) 
Design of qPCR 
primer sequences 
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2.2 Methods 
2.2.1 Mouse studies 
Gata-1low mice have originally been generated by targeted mutation in the promotor 
region for the Gata1 gene which results in impaired expression of the transcription 
factor Gata-1 in megakaryocytes.229 While Gata-1 expression is reduced, 
megakaryocytes retain a high proliferation rate, remain immature and release 
reduced platelet numbers. Further, Gata-1low mice develop fibrosis in the bone 
marrow that resembles the development of myelofibrosis in PMF patients.230 The 
Gata1 gene is located on the X chromosome, hence breeding of Gata-1low mice 
aimed at generating homozygous females and hemizygous males. A breeding colony 
was started by crossing two heterozygous female Gata-1low mice with two male wild 
type (WT) littermates. Mice were maintained according to standard protocols at the 
animal facility at Center for Cardiovascular Research at Charité – 
Universitätsmedizin (Berlin, Germany). 3 weeks after birth, mice received ear 
notches for identification and to provide tissue for genotyping. 
2.2.1.1 Genotyping 
For DNA isolation, ear punches were placed in 75 µl DNA extraction solution I and 
incubated at 98°C for 1 h. After cooling, 75 µl DNA extraction solution II were added 
for neutralization. The samples were centrifuged at 4000xg for 3 min and the DNA 
solution was transferred to a new tube. All littermates were genotyped by PCR 
according to the standard protocol provided by Jackson Laboratory. The following 
duplex PCR reaction was used: 





in an upscaled premix 





∑ 12 µl 
2.4 µl 5x GoTaq® buffer 
0.24 µl dNTPs 
0.6 µl Primer Gata-1low forward  
0.6 µl Primer Gata-1low forward  
0.3 µl Primer WT forward 
0.3 µl Primer WT reverse 
0.06 µl GoTaq® polymerase 
2 µl DNA   
  
2  MATERIALS AND METHODS  33 
 
PCR products were amplified using the following temperature program: 
94°C 3 min   
94°C 30 sec  
35 cycles 58°C 1 min  
72°C 1 min  
72°C 2 min   
10°C up to 12 h   
 
The PCR products were subsequently separated by agarose gel electrophoresis, 
using 1% agarose in TAE buffer containing 5 µl ethidium bromide solution per 100 ml 
agarose gel. A DNA ladder was loaded on the gel as a size marker. Visualization by 
ultraviolet (UV) light enabled detection of a 220 basepair (bp) product in WT mice, a 
370 bp product in Gata-1low mice, or both PCR products in heterozygous mice 
(exemplarily shown in Figure 2.1).  
 
Figure 2.1: Visualization of polymerase chain reaction (PCR) products from genotyping of a mouse cohort, 
separated on a 1% agarose gel. The wild type (WT) gene generates a 220 basepair (bp), the Gata-1low mutation 
a 370 bp PCR product. HET: heterozygous, HOM: homozygous. 
For experiments, Gata-1low mice and age-matched WT littermates were sacrificed by 
isoflurane overdose at 5, 10 and 15 months of age. Whole blood was collected post 
mortem, and femurs were dissected and frozen in liquid nitrogen for RNA isolation, 
or fixed in 4% phosphate-buffered formaldehyde for histological procedures. 
2.2.2 Blood cell counts 
Murine blood was collected directly post mortem from cardiac puncture into 1.2 ml 
EDTA tubes. The tubes were inverted to mix and whole blood was analyzed within 
6 h from sample collection using a hematology analyzer. 
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2.2.3 Gene expression analyses 
2.2.3.1 RNA isolation 
Total RNA was obtained from whole murine femurs by pulverizing the frozen bone 
with a cooled pestle. The pulverized, frozen tissue was dissolved in 1.5 ml TRI 
reagent® and incubated for 5 min at room temperature. 300 µl chloroform were 
added to the mixture, inverted and incubated for 3 min at room temperature. The 
mixture was centrifuged for 15 min at 12,000xg at 4°C and the upper, RNA containing 
aqueous phase was transferred to a new tube. 700 µl isopropanol were added to the 
aqueous phase, inverted, and incubated for 10 min at room temperature. The sample 
was centrifuged for 10 min at 12,000xg at 4°C to pellet the precipitated RNA and the 
supernatant was subsequently discarded. The pellet was washed twice with 1.5 ml 
75% EtOH, followed by centrifugation for 5 min at 7,500xg at 4°C. After discarding 
the washing solution, the RNA pellet was air-dried and resuspended in 30 µl pure 
H2O. All further RNA handling steps were carried out on ice, and RNA concentration 
was determined by spectrophotometric analyses using NanoDrop®. 
2.2.3.2 RNA sequencing 
Total RNA from whole femurs of 10-month-old mice (n=3 Gata-1low vs. n=3 WT) was 
used for RNA sequencing (RNAseq) analyses. RNAseq and bioinformatics were 
performed by Microsynth AG (Balgach, Switzerland) and hence, devices and 
reagents for RNAseq are not listed in the ‘Materials’ section. In brief, RNA quality 
was evaluated by Microsynth on Agilent 2100 BioAnalyzer (Santa Clara, Ca, USA), 
library preparation including poly(A) enrichment was done using Illumina stranded 
TruSeq RNA library including poly(A) enrichment (San Diego, CA, USA). Sequencing 
was conducted with 1x75 bp reads and 30 million reads per sample. Reads were 
mapped to the mouse genome, counts were normalized and analyzed for differential 
expression. Genes of interest were plotted using GraphPad Prism. Significantly 
upregulated genes were further used for gene ontology (GO) enrichment analysis.231 
PANTHER overrepresentation test using the GO molecular function annotation data 
set and Fisher’s exact test were applied. 
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2.2.3.3 cDNA synthesis 
1 µg RNA per sample was diluted up to 9 µl with pure H2O and used as template for 
reverse transcription. One reaction included: 
9 µl diluted RNA (1 µg)  
 
 
∑ 20 µl 
10 µl 2x buffer 
 
previously prepared in 
an upscaled premix 1 µl reverse transcriptase 
 
A separate reaction included diluted RNA and buffer, omitting reverse transcriptase, 
serving as a negative control in primer validation experiments (‘‒RT control’).  The 
reactions were prepared in PCR reaction tubes and cDNA was synthesized in a PCR 
cycler running a program of 1 h at 37°C, followed by 5 min enzyme inactivation at 
95°C. The 20 µl reaction was finally diluted up to a final volume of 100 µl with pure 
H2O. 
2.2.3.4 Quantitative polymerase chain reaction 
To analyze the expression levels of specific genes, qPCR was performed using 
SYBR® Green. Primers were used at a final concentration of 100 nM, each reaction 
contained: 
 
10 µl SYBR® Green  
previously prepared in   
an upscaled premix        
for each gene 
∑ 20 µl 
0.2 µl Primer forward (10 µM) 
0.2 µl Primer forward (10 µM) 
8.6 µl Pure H2O 
1 µl cDNA  
 
Gene amplification was measured using a quantitative real-time PCR cycler applying 
the following temperature program: 
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50°C 2 min   
95°C 10 min   
95°C 15 sec  
40 cycles 
60°C 1 min  
95°C 1 min   
55°C 30 sec   
95°C 30 sec   
 
Each gene was measured in triplicates. All primer pairs were tested using cDNA 
dilutions series (1:4, 1:16, 1:64) to evaluate amplification efficiency and each primer 
pair was tested for amplification of genomic DNA in ‒RT controls. Every experiment 
further included a template-omitting negative control to rule out detection of primer 
dimers or nucleic acid contaminations. mRNA levels were calculated in relative units 
using the 2-ΔΔCt method232 with Hprt as a reference gene for normalization. Values 
observed in age-matched WT control mice served as reference. 
2.2.4 In situ methods 
Murine femurs were fixed in 4% phosphate-buffered formaldehyde for 6 h and 
decalcified in decalcification solution for 7 days with daily changes of the solution. 
Femurs were further processed in a citadel allowing dehydration, clearing and 
paraffin infiltration using the following program: 
 
70% EtOH  1 h 
80% EtOH  1 h 
96% EtOH  1 h 
100% EtOH (1) 1 h 
100% EtOH (2) 1 h 
Neo-Clear® (1) 40 min 
Neo-Clear® (2) 40 min 
Paraffin type 6 1 h 
Paraffin type 9 up to 12 h 
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Femurs were afterwards paraffin-embedded and cooled paraffin blocks were cut into 
1 µm sections using a microtome. The cut sections were then floated onto a water 
bath to eliminate wrinkles and transferred to microscopic slides. The tissue slides 
were dried at 60°C for 90 min and subsequently stored at -20°C to ensure optimal 
preservation of epitope integrity. 
2.2.4.1 May-Grünwald Giemsa staining 
For histological evaluation of blood and progenitor cells in the bone marrow, a 
combination of May-Grünwald and Giemsa staining was used. Tissue slides were 
deparaffinized in Neo-Clear® (2x5 min), followed by rehydration in graded EtOH 
(100%, 96%, 80%, 70%) for 3 min each, transferred to H2O and immersed in 
methanol for 5 min. The slides were incubated in May-Grünwald staining solution for 
5 min and directly transferred into Giemsa staining solution for 45 min. 1% acetic 
acid solution was used to destain the tissue, which was afterwards rinsed in H2O. 
Finally, slides were dehydrated in 96% EtOH, 100% EtOH and Neo-Clear® for 3 min 
each, and mounted using anhydrous mounting medium. 
2.2.4.2 Reticulum staining 
In order to visualize fibrotic changes in the bone marrow of Gata-1low mice, femur 
sections were stained for reticulum fibers. All solutions used for the staining were 
part of a Reticulum Stain Kit listed in 2.1.6. Slides were deparaffinized and rehydrated 
in graded EtOH as described above. The tissue slides were then transferred to H2O 
and placed in potassium permanganate solution for 10 min. The slides were quickly 
rinsed in three changes of H2O, differentiated in potassium metabisulfite solution and 
again rinsed in three changes of H2O. Slides were transferred to ferric ammonium 
sulfate solution for 10 min and rinsed in two changes of H2O. Tissue sections were 
then stained in ammoniacal silver solution for 3 min, washed in three changes of 
H2O, followed by 1 min incubation in formalin solution. After washing in three changes 
of H2O, the slides were transferred to a gold chloride solution for 5 min. To remove 
unreduced silver, the slides were placed in sodium thiosulfate solution for 2 min and 
rinsed in tab water for 2 min. Nuclei were counterstained with fast red solution for 
3 min, quickly rinsed in tab water followed by H2O. The tissue was finally dehydrated 
in three changes of 100% EtOH and mounted with anhydrous mounting medium. 
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2.2.4.3 Multiplexed immunohistochemistry 
In order to detect multiple epitopes within the bone marrow, multiplexed fluorescence 
staining of femur sections was performed using tyramide fluorophores (Opal™ 
fluorophores), which form a stable fluorescent precipitate after catalyzation by 
horseradish peroxidase (HRP).233 Hence, proteins can be detected using primary 
antibodies and HRP-conjugated secondary antibodies in situ. Both antibodies can be 
removed from the tissue after staining, whereas the stable, heat-resistant 
fluorophore-precipitate is not affected by the antibody removal procedure. This allows 
the consecutive staining of multiple proteins, without the need of using different 
antibody species. 
Slides were deparaffinized and rehydrated in graded EtOH as described above, 
transferred to antigen retrieval buffer and heated in a microwave. The slides were 
then kept simmering in a microwave for 20 min. All other staining steps were carried 
out at room temperature, all washing steps were carried out under agitation. Slides 
were washed in two changes of TBS-T for 5 min each and the tissue was sectioned 
using a hydrophobic barrier pen. Unspecific binding sites were blocked for 10 min, 
followed by incubation with primary antibody for 30 min. Slides were washed in three 
changes of TBS-T, 5 min each, and incubated with HRP-conjugated secondary 
antibodies for 10 min. Slides were again washed in three changes of TBS-T and 
incubated with Opal™ fluorophores for 10 min, followed by washing in TBS-T. The 
antigen retrieval step was subsequently repeated to remove primary and secondary 
antibodies. This procedure was repeated for staining of other targets. Nuclei were 
counterstained with DAPI for 5 min, the slides were finally washed in three changes 
of TBS-T and mounted with ProLong™ Diamond Antifade mounting medium. Imaging 
was performed with the Vectra® Polaris™ system. Hereby, a whole slide scan was 
first acquired at ×10 magnification to image the whole bone and region selection for 
multispectral imaging was performed using Phenochart™ software. Ten multispectral 
images at ×40 magnification were acquired. Autofluorescence elimination, spectral 
unmixing, generation of pseudo-brightfield IHC images and quantification was 
performed with inForm® software. 
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2.2.4.4 Proximity Ligation Assay 
PLA is an antibody-based, sensitive means which can be used to quantify protein 
expression, protein-protein-interactions and protein phosphorylation. Hereby, two 
oligonucleotide-coupled secondary antibodies (PLA probes) detect a single or two 
different primary antibodies. Through ligation, PLUS and MINUS oligonucleotides are 
joined to a circle when in close proximity and serve as template for polymerization. 
A polymerase replicates the DNA using fluorescently labeled nucleotides and a 
concatemeric product is generated. The resulting rolling circle product (RCP) can be 
visualized and quantified as a distinct, fluorescent dot.  
 
Figure 2.2: Schematic illustration of proximity ligation assay (PLA) approaches used in this study for the analysis 
of A Platelet-derived growth factor receptor (PDGFR) expression, B PDGFRβ–PDGF-B interaction, C PDGFRβ 
phosphorylation and D PDGFRβ–TC-PTP interaction. Each assay uses primary antibodies, which are bound by 
specific oligonucleotide-conjugated secondary antibodies (PLA probes). Oligonucleotides are ligated when both 
probes are in close proximity, and a rolling circle product is generated in an amplification reaction using 
fluorescent nucleotides. The rolling circle product can be detected in situ as a fluorescent dot. 
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In this study, PLA was used to quantify protein expression in a single recognition 
approach (Figure 2.2A) as well as protein-protein-interactions (Figure 2.2B and D) 
and protein phosphorylation (Figure 2.2C). 
All solution and reagents used, if not otherwise stated, were part of the Duolink® PLA 
kits. Slides were deparaffinized and rehydrated in graded EtOH as described above. 
Tissue areas were sectioned using a hydrophobic barrier pen and autofluorescence 
elimination reagent was incubated on the tissue for 20 min. The tissue slides were 
then rinsed in 70% EtOH and transferred to H2O. Slides were transferred to antigen 
retrieval buffer and heated to boiling in a microwave for 5 min. Slides were allowed 
to cool down for 45 min, followed by washing in three changes of TBS-T. Nonspecific 
binding sites were blocked for 60 min and the sections were incubated with 
antibodies at 4°C over night. Primary antibodies and dilutions are listed in Table 2.1 
and the antibody combinations for the different assays are listed in Table 2.4 below. 
Unbound antibodies were removed by washing the slides in two changes of TBS-T 
for 5 min each, and the slides were incubated with oligonucleotide-conjugated 
secondary antibodies (PLA probes) for 1 h at 37°C. Subsequently, slides were 
washed twice in TBS-T for 5 min. A ligation mixture was incubated on the slides for 
30 min at 37°C. Slides were washed in two changes of TBS-T and then incubated 
with the diluted amplification mixture for 100 min at 37°C. After amplification, the 
slides were washed in two changes of wash buffer, 10 min each, and rinsed in H2O 
for 1 min. The slides were mounted using Fluoroshield™ mounting medium with DAPI 
to stain the nuclei. Cells were visualized using an epifluorescence microscope 
(BZ-9000, Keyence) with filters for DAPI and TRITC and a 60x objective. RCPs were 
quantified using Duolink® Image Tool. For clarity in printing, images shown where 
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Table 2.4: Antibody combinations used in the different proximity ligation assay (PLA) approaches for the 
analysis of protein-protein interactions and protein phosphorylation.  
Assay Rabbit primary antibodies Mouse primary antibodies 
PDGFRβ–PDGF-B interaction PDGF-B PDGFRβ 42G12 
PDGFRβ tyrosine phosphorylation PDGFRβ Y92 Pan-pY pY100 
Pan-pY pY20 
Pan-pY 4G10 
PDGFRβ–TC-PTP interaction PDGFRβ Y92 TC-PTP F-8 
2.2.5 In vitro methods 
NIH-3T3 fibroblasts were maintained in DMEM containing 10% FBS and 1% 
penicillin/streptomycin in a 5% CO2 atmosphere at 37°C. Cells were routinely split 
1:5 by washing the cells with pre-warmed PBS and detaching the cells using 
trypsin/EDTA before reaching a confluence greater than 90%. 
2.2.5.1 Immunofluorescence staining 
NIH-3T3 fibroblasts were seeded into chamber slides and the following day, cells 
were placed on ice, washed with ice-cold PBS and fixed with 4% buffered formalin 
for 10 min at room temperature. Cells were washed in three changes of PBS, 5 min 
each, and permeabilized with 0.1% Triton™ X-100 for 10 min. Cells were again 
washed in three changes of PBS and unspecific binding sites were blocked for 1 h. 
Cells were then incubated with primary antibodies at 4°C over night. Slides were 
washed in three changes of PBS and incubated with secondary antibodies for 1 h at 
room temperature. The cells were washed in three final changes of PBS, the chamber 
was removed from the slide and cells were mounted using Fluoroshield™ mounting 
medium with DAPI. Cells were visualized using an epifluorescence microscope 
(BZ-9000, Keyence) with filters for DAPI, green fluorescent protein (GFP) and TRITC, 
and a 60x objective. 
2.2.5.2 Transfection and PDGF-BB treatment 
For transfection, cells were seeded into 6 well plates, grown to reach 40-50% 
confluence and then changed to Opti-MEM® transfection medium. In two separate 
reaction tubes, 75 pmol siRNA and 5 µl Lipofectamine were diluted up to 150 µl with 
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Opti-MEM®, respectively. The dilutions were incubated for 5 min at room 
temperature, then combined and incubated for 20 min at room temperature. The 
diluted siRNA-lipid complexes (∑300 µl per well) were added to the cells, the final 
concentration of siRNA in the medium was 30 nM. After 16-20 h, cells were changed 
to normal growth medium. 
48 h after transfection, nontargeting control and Ptpn2 knockdown cells were growth-
arrested for 24 h in serum-free DMEM with 100 µg/ml BSA. 72 h after transfection, 
cells were treated with 50 ng/ml PDGF-BB in DMEM for 5 min, the medium in control 
wells was changed to fresh DMEM containing 100 µg/ml BSA. Immediately after 
stimulation, cells were placed on ice and washed with three changes of ice-cold PBS. 
Remaining PBS was removed and 150 µl lysis buffer containing protease and 
phosphatase inhibitors were added to each well. The cells were detached from the 
wells using a cell scraper and the lysate was transferred to a reaction tube. All 
subsequent protein handling steps were carried out on ice. The lysates were 
centrifuged for 20 min at 12,000xg at 4°C to pellet cell debris and the lysate was 
transferred to a new tube. Concentrations of the protein solutions were determined 
using Bradford assay by measuring extinction of the protein-dye complexes at 
595 nm.234 Concentrations were determined by generating a standard curve with 
BSA dilution series (0-2 mg/ml). Protein lysates were stored at -20°C (short term, 
<7 days) or at -80°C (long term, >7 days). 
2.2.5.3 Sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
20 µg protein per lane were diluted with protein loading buffer, denaturated at 95°C 
for 5 min and separated using SDS-PAGE. 3.9% stacking gels and a 10% separation 
gels were composed as follows: 
 
 Separation gel Stacking gel 
Pure H2O 4 ml 3 ml 
Buffer 2.5 ml                             
(1.5 M Tris-HCl, pH 8.8) 
1.25 ml                            
(0.5 M Tris-HCl, pH 6.8)  
10% SDS solution 100 µl 50 µl 
Acrylamide/bis (30%) 3.3 ml 0.65 ml 
10% APS solution 50 µl 50 µl 
TEMED 5 µl 6 µl 
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PageRuler™ prestained protein ladder served as molecular weight estimate. The 
gels were run in electrophoresis buffer, initially at 80 V to allow proteins to pass the 
stacking gel, and subsequently at 120 V for protein separation.  
2.2.5.4 Immunoblotting 
After complete separation, proteins were transferred to a membrane for immunoblot 
(IB) analyses. The gels were washed in transfer buffer and proteins were transferred 
to a PVDF membrane by tank blotting. Prior to blotting, the PVDF membrane was 
activated with methanol and positioned on top of the gel between two blotting papers 
and two sponges to stack a blotting ‘sandwich’, which was placed in blotting 
cassettes inside a blotting chamber filled with transfer buffer and an ice container. 
The transfer was run at 100 V for 1 h and the membranes were washed in three 
changes of TBS-T for 5 min each. Membranes were subsequently cut into stripes 
containing the molecular weight region of interest and unspecific binding sites were 
blocked for 1 h before incubation with primary antibodies at 4°C over night. 
Membrane stripes were then washed in three changes of TBS-T, 5 min each, and 
incubated with HRP-conjugated secondary antibodies for 1 h at room temperature. 
The membrane stripes were finally washed in three changes of TBS-T, 10 min each, 
and proteins of interest were detected using chemiluminescence for visualization. 
For immunodetection, films optimized for chemiluminescence signal detection were 
used. After visualization, membranes were washed in three changes of TBS-T, and, 
if applicable, antibodies were stripped from the membranes by incubation in three 
changes of stripping buffer, 20 min each. Membranes were washed in three changes 
of TBS-T and the blocking and antibody incubation steps were repeated. For protein 
quantification, densitometric analyses were performed using ImageJ software. 
β-Actin and GAPDH served as reference proteins for normalization. For 
phosphorylation site-specific antibodies, signals were normalized to the protein 
expression of the cognate protein. 
2.2.5.5 Proliferation assay 
NIH-3T3 fibroblasts were transfected as described in 2.2.5.2. 48 h after transfection, 
cells were seeded into 96 well plates at 1000 cells/well. 6 h after cell seeding, cells 
were growth-arrested for 24 h in DMEM with 100 µg/ml BSA before changing to the 
indicated culture media. Proliferation was monitored using IncuCyte® Live-Cell 
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Imaging system. Four phase contrast images per well at 10x magnification were 
acquired in 3 h intervals for six days. Proliferation was analyzed using IncuCyte® 
software and results are shown as occupied area in percent confluence over time 
with standard error. 
2.2.6 Statistics 
All results that are presented as boxplots show the median with whiskers 
representing minima and maxima, the number of mice (n) per group are displayed as 
individual points within the boxes. Bar graphs show mean and standard deviation. 
Statistical differences between a Gata-1low and the age-matched WT control group 
were determined using unpaired Student’s t test. For comparison of multiple groups, 
analysis of variance with posthoc Tukey correction was used. Statistical analyses 
were performed using GraphPad Prism. P < 0.05 was considered significant; 
significant differences are indicated as asterisks: 
* P < 0.05 
** P ≤ 0.01 
*** P ≤ 0.001 
**** P ≤ 0.0001 
Absence of asterisks indicates non-significance. 
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3 RESULTS 
3.1 Development of myelofibrosis in Gata-1low mice  
Gata-1low mice have an impaired Gata-1 expression in megakaryocytes and 
phenotypically resemble characteristics of PMF patients.230,235 This study aimed at 
characterizing Gata-1low mice at three stages of disease development: 5 months, 
10 months and 15 months of age. The X-linked inheritance of the mutation led to a 
surplus in hemizygous males during breeding. In accordance with the literature, 
Gata-1low mice of both sexes were viable, fertile and did not show any apparent 
abnormalities. While the literature suggests that Gata-1low mice reach normal life 
expectancy, higher mortality was observed in homozygous females compared to 
heterozygous males. Three homozygous females intended for analysis at 15 months 
of age died between 8 and 13 months of age, only one homozygous female reached 
the age of 15 months. The reduced survival of female mice suggests a harsher or 
potentially earlier onset of the disease in homozygous females. Hence, blood cell 
counts of male and female mice were compared to reveal potential sex-specific 
discrepancies (Table 3.1). However, the small number of female, homozygous 
Gata-1low mice partly impeded conclusive statistical analyses, and for female, 
homozygous Gata-1low mice at 15 months of age (n=1), statistical analysis was not 
applicable. However, there were slight, but statistically significant differences in 
blood cell counts of both sexes in 10-month-old Gata-1low mice (red blood cell counts, 
P=0.0489) and 15-month-old WT mice (red blood cell counts, P=0.0491; white blood 
cell counts P=0.0218; and platelet counts, P=0.0022). In addition to potential 
differences in disease progression in female Gata-1low mice, the sex-specific 
discrepancies in WT mice indicate noticeable, age-dependent biological variations in 
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Table 3.1: Blood cell counts from wild type (WT) and Gata-1low mice of both sexes at 5 months (5 M), 10 months 
(10 M) and 15 months (15 M) of age. Highlighted cells indicate significant differences between male and female 
mice. RBC: red blood cell counts, WBC: white blood cell counts, PLT: platelet counts, m in: minimum value, 
max: maximum value, SD: standard deviation. 
 sex n RBC [x106/µl] WBC [x103/µl] PLT [x103/µl] 










5 M WT 
♂ 7 
8.60 
(7.35 – 9.52) 
0.82 
4.84 
(2.2 – 8.4) 
2.00 
1257.57 




(8.36 – 9.27) 
0.39 
2.78 
(2.0 – 3.6) 
0.67 
1265.75 
(1151 – 1445) 
125.86 
5 M Gata-1low 
♂ 8 
7.14 
(5.72 – 8.19) 
0.85 
6.75 
(2.4 – 12.4) 
3.05 
94.63 




(7.14 – 8.32) 
0.66 
8.37 
(6,4 – 10.2) 
1.90 
227.00 
(41 – 584) 
309.26 
10 M WT 
♂ 10 
8.66 
(8.18 – 9.32) 
0.43 
4.37 
(3.2 – 6.7) 
1.21 
1537.40 




(7.56 – 8.83) 
0.48 
3.64 
(2.2 – 5.3) 
1.22 
1241.60 
(1084 – 1648) 
232.47 
10 M Gata-1low 
♂ 8 
6.46 
(5.21 – 7.09) 
0.63 
8.70 
(5.9 – 17.4) 
4.36 
83.13 




(7.08 – 7.56) 
0.25 
7.30 
(4.7 – 9.8) 
2.55 
145.00 
(63 – 308) 
141.16 
15 M WT 
♂ 9 
8.71 
(8.14 – 9.20) 
0.49 
5.73 
(3.3 – 11.9) 
2.64 
1610.00 




(6.87 – 8.74) 
0.74 
2.87 





15 M Gata-1low 
♂ 10 
6.37 
(5.53 – 7.20) 
0.56 
9.63 
(4.2 – 14.1) 
3.03 
82.91 
(23 – 336) 
88.11 
♀ 1 5.70 n/a 12.10 n/a 18.00 n/a 
 
To minimize heterogeneity in this age-dependent study, especially in the advanced 
disease stage (15 months), all experiments shown were carried out using male, 
hemizygous Gata-1low and male, age-matched WT control mice.  
Male Gata-1low mice of all ages were normal in body weight (Figure 3.1A). As early 
as 5 months of age, Gata-1low mice developed a pronounced splenomegaly (Figure 
3.1B). However, liver weight remained normal at all ages (Figure 3.1C), suggesting 
that the spleen is the main site of extramedullary hematopoiesis. Gata-1low mice 
developed time-dependent, progressive anemia, as indicated by a steady decrease 
in red blood cells (Figure 3.1D). Further, an increase in white blood cells implied a 
moderate leukocytosis starting at month 10 (Figure 3.1E). The number of platelets 
was massively reduced in Gata-1low mice at all ages (Figure 3.1F).  




Figure 3.1: Characteristics of the Gata-1low mouse model for primary myelofibrosis at 5 months (5 M), 10 months 
(10 M) and 15 months (15 M) of age. A Body weight of Gata-1low mice and age-matched wild type (WT) controls. 
B Spleen weight per g body weight. C Liver weight per g body weight. D Red blood cell (RBC) counts. E White 
blood cell (WBC) counts F Platelet (PLT) counts. 
In order to specify the time range which is signified by collagen production in the 
bone marrow of Gata-1low mice, type I collagen Col1a1 (Figure 3.2A) and type III 
collagen Col3a1 (Figure 3.2B) gene expression were analyzed by qPCR. There was 
a significant decrease of Col1a1 gene expression in the bone marrow of 5-month-old 
Gata-1low mice. However, a marked increase in gene expression of the two collagens 











Figure 3.2: Gene expression of collagens in the bone marrow of Gata-1low mice at 5 months (5 M), 10 months 
(10 M) and 15 months (15 M) of age. qPCR analyses of A type I collagen Col1a1 and B type III collagen Col3a1 
in the bone marrow of Gata-1low mice and age-matched wild type (WT) controls.  
In order to evaluate pathological changes in the bone marrow of Gata-1low mice, cells 
within the femoral bone marrow were visualized using May-Grünwald Giemsa 
staining (Figure 3.3, upper panel). As indicated by black arrows, high numbers of 
dysplastic megakaryocytes were found in the bone marrow of Gata-1low mice at all 
ages. To determine fibrotic stages in Gata-1low mice, bone marrow was stained for 
reticulum fibers (Figure 3.3, lower panel). No apparent accumulation of reticulum 
fibers was observed in the bone marrow of Gata-1low mice at month 5, but there was 
an increased deposition of stained fibers at month 10. At 15 months of age, a 
pronounced accumulation of reticulum fibers was detected in the bone marrow (red 
arrowheads). Hence, month 5 was defined as a pre-fibrotic, month 10 as an early 
fibrotic, and month 15 as an overt fibrotic stage in Gata-1low mice.  
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Figure 3.3: Representative images of the femoral bone marrow of Gata-1low mice and wild type (WT) controls at 
5 months (5 M), 10 months (10 M) and 15 months (15 M) of age. May-Grünwald Giemsa staining showing 
dysplastic megakaryocytes (upper panel, black arrows) and reticulum staining showing increasing amount of 
reticulum fibers (lower panel, red arrowheads) in the bone marrow of Gata-1low mice. Scale bars = 50 µm. 
3.2 Transcriptome analyses in early fibrotic bone marrow 
It has previously been observed that collagen gene expression was highly 
upregulated in early fibrotic bone marrow of Gata-1low mice at 10 months of age. 
Hence, transcriptomic changes in this very stage were investigated by whole 
transcriptome RNAseq. Differential gene expression analyses of n=3 Gata-1low vs. 
n=3 WT mice revealed a total of 1503 upregulated and 1604 downregulated genes. 
Since RTKs and RTK-activating ligands have been attributed an important role in 
myelofibrosis, it was further focused on transcriptomic changes of RTKs (Figure 
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3.4A) and their cognate ligands (Figure 3.4B). Interestingly, a high number of RTKs 
showed a significant increase in gene expression, among those, Flt1, Fgfr1, Ptk7, 
Tie1 and the PDGF receptors Pdgfra and Pdgfrb. Only three RTKs showed significant 
decrease in gene expression (Epha7, Fgfrl1 and Mertk). Although many ligands were 
not significantly regulated in early fibrotic bone marrow of Gata-1low mice, an 
induction of Angpt2, Angpt4, Efna2, Efnb1, Igf2, Pgf and Ptn was observed. Gene 
expression of three ligands (Figf, Igf1, Kitl,) was decreased.  
 
Figure 3.4: RNA sequencing analyses showing differential gene expression of receptor tyrosine kinases (RTKs) 
and their ligands. Total RNA from femoral bone marrow of mice at 10 months of age (n=3 Gata-1low vs. n=3 wild 
type mice) was analyzed. A Differential gene expression of RTKs. B Differential gene expression of their 
cognate ligands. ns: not significant. 
In order to classify all transcriptionally upregulated genes to their biological function, 
GO enrichment analyses were performed. These analyses aimed at identifying 
biological pathways of genes, which were statistically enriched within the gene 
expression data set. GO enrichment analyses revealed different implications of the 
1503 upregulated genes (Figure 3.5). Interestingly, genes implicated in PDGF 
binding were most overrepresented within the upregulated genes. As per GO 
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molecular function annotation data set, the term ‘PDGF binding’ includes all 
selectively and non-covalently PDGF-interacting gene products (i.e. PDGF ligands, 
receptors and type I - VI collagens). These were followed by ECM structural 
constituents and genes involved in collagen binding. 
 
Figure 3.5: Gene ontology (GO) enrichment analysis of overexpressed genes. Results are based on RNA 
sequencing data from femoral bone marrow of mice at 10 months of age (n=3 Gata-1low vs. n=3 wild type mice). 
PDGF: platelet-derived growth factor, ECM: extracellular matrix, RTK: receptor tyrosine kinase.  
3.3 Expression of PDGFs and their receptors in the bone marrow 
In order to characterize the expression dynamics of PDGF signaling components in 
different stages of bone marrow fibrosis, gene expression of the receptor and ligand 
genes in the bone marrow Gata-1low mice were analyzed by qPCR (Figure 3.6). Here, 
highly induced gene expression of both receptor genes Pdgfra and Pdgfrb was 
observed in early fibrotic bone marrow from Gata-1low mice at 10 months of age and 
remained increased in overt fibrotic bone marrow of 15-month-old Gata-1low mice 
(Figure 3.6A and B). Interestingly, Pdgfrb gene expression was significantly 
decreased in pre-fibrotic bone marrow of 5-month-old Gata-1low mice, as previously 
detected for Col1a1 gene expression in that very stage. qPCR analyses of the ligand 
genes Pdgfa and Pdgfb revealed a major increase in ligand gene expression at the 
early fibrotic stage (Figure 3.6C and D). Again, a decrease in Pdgfa gene expression 
in pre-fibrotic bone marrow was observed, whereas Pdgfa gene expression was 
increased in early and overt fibrotic bone marrow. Pdgfb gene expression was 
significantly upregulated only in early fibrotic bone marrow and remained nearly at a 
baseline level in pre-fibrotic and overt fibrotic bone marrow of Gata-1low mice.  
3  RESULTS  52 
 
 
Figure 3.6: Gene expression of platelet-derived growth factors (PDGFs) and their receptors in the bone marrow 
of Gata-1low mice and age-matched wild type (WT) controls at 5 months (5 M), 10 months (10 M) and 15 months 
(15 M) of age. qPCR analyses of A Pdgfra, B Pdgfrb, C Pdgfa and D Pdgfb. 
To visualize the expression of the PDGF signaling components within the bone 
marrow, multiplexed IHC staining of the PDGF signaling components was performed 
(Figure 3.7). This technique uses fluorescent tyramide HRP substrates, which form 
stable complexes that allow for staining of multiple proteins in one tissue section. 
Multispectral imaging was used for the detection of signals, which were subsequently 
unmixed to generate pseudo-single stained images. The multiplexed images within 
this work hence show staining of the different proteins in one and the same tissue 
section, and for a comprehensive comparison between the detected proteins, images 
































Figure 3.7: Multiplexed immunohistochemical (IHC) staining of platelet-derived growth factors (PDGFs) and 
their receptors in the bone marrow of Gata-1low mice at 5 months (5 M), 10 months (10 M) and 15 months (15 M) 
of age. Representative images showing femoral bone marrow of Gata-1low mice and wild type (WT) control mice 
stained for PDGF receptor α (PDGFRα, yellow), PDGF receptor β (PDGFRβ, green), PDGF-A (cyan) and 
PDGF-B (magenta). Nuclei were counterstained with DAPI (blue), scale bars in lower panels = 50 µm. 
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PDGFRα expression (yellow) was detected predominantly in megakaryocytes, both 
in WT and in Gata-1low mice. PDGFRβ staining (green) was seemingly increased in 
early and overt fibrotic bone marrow of Gata-1low mice and marked spindle-shaped 
cells, which typically represent stromal cells, such as fibroblasts. Staining of the 
ligand PDGF-A (cyan) showed expression in a wide variety of different hematopoietic 
cells, whereas PDGF-B (magenta) mainly derived from megakaryocytes both in WT 
and in Gata-1low mice, suggesting a mostly paracrine effect of PDGF-B on PDGFRβ 
in the bone marrow. 
To evaluate the cell-specific expression of PDGF receptors and ligands more clearly, 
the unmixed imaging data from multiplexed IHC were used to generate pseudo-
brightfield IHC images (Figure 3.8). Exemplarily, bone marrow sections from 
10-month-old Gata-1low mice was used to include fibrosis-associated PDGFRβ-
positive staining. These higher magnification images visualize more explicitly the 
megakaryocyte-specific expression of PDGF-A, -B and PDGFRα (black arrows). 
PDGF-A expression, although in low intensity, was seen more widely in other 
hematopoietic cells compared to PDGF-B expression, which was strongest in 
megakaryocytes. Megakaryocytes were clearly negative for PDGFRβ expression, but 




Figure 3.8: Pseudo-brightfield immunohistochemistry (IHC) images of platelet-derived growth factors (PDGFs) 
and their receptors in the bone marrow of Gata-1low mice. PDGF-A, PDGF-B and PDGF receptor α (PDGFRα) 
expression in megakaryocytes is indicated by black arrows and PDGFRβ expression in spindle-shaped stromal 
cells is indicated by black arrowhead. Images are exemplary from bone marrow of a Gata-1low mouse at 
10 months of age. Scale bars = 20 µm. 
3  RESULTS  55 
 
 
Although primary antibodies detect the different isoforms specifically, it must be 
notes that PDGF ligands are synthesized as dimers (PDGF-AA and -BB homo-, and 
PDGF-AB heterodimers) and do not exist as functional protein monomers. The 
antibodies used in this study, however, detect peptide sequences within protein 
monomers, and hence might detect homo- as well as heterodimers. Consequently, 
the notations within antibody-based detection methods in this study refer to the PDGF 
ligands, physiologically inapplicable, as ‘PDGF-A’ and ‘PDGF-B’. 
The data acquired by multiplexed IHC provide a solid means to quantify protein 
expression of the different PDGF signaling components. In order to apply an even 
more sensitive method for protein quantification, an in situ PLA in a single recognition 
approach was used (see Figure 2.2A in the ‘Methods’ section for assay principle). 
The assay is based on proximity-mediated ligation of two probes and an amplification 
reaction which results in the creation of signals. These signals, also referred to as 
rolling circle products (RCPs), are detectable and quantifiable in the tissue as 
distinct, fluorescent dots. In the PLA single recognition approaches, the tissue 
sections were incubated with single, specific primary antibodies. Technical negative 
controls were generated by incubation with normal mouse and rabbit IgG 
(Figure 3.9). All negative controls within this study utilized tissue that typically yields 
highest signal strengths for the respective method, hence bone marrow section from 
15-month-old Gata-1low mice was used for negative controls in antibody-based 
assays. In PLA negative controls, 1-2 false-positive signals (RCPs) per 100 cells 
were typically detected. 
 
Figure 3.9: Technical negative control for the different proximity ligation assay (PLA) approaches. Bone marrow 
from Gata-1low mice at 15 months of age were incubated with normal mouse, normal rabbit immunoglobulin G 
(IgG), or a combination of both. Scale bars = 20 µm. 
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For methodical validation of the quantitative analysis by PLA, PDGFRβ and PDGF-B 
protein expression was analyzed by single recognition PLA. The acquired PLA data 
were directly compared to quantified protein expression data from multiplexed IHC 
(Figure 3.10A). Comparing PDGFRβ protein expression data from multiplexed IHC 
(Figure 3.10B) to PDGFRβ protein expression data from PLA (Figure 3.10C), very 
good conformity of results was seen. Representative images of quantified RCPs are 
depicted in the upcoming protein expression analyses section. When comparing 
PDGF-B protein expression data from multiplexed IHC (Figure 3.10D) to PDGF-B 
protein expression data from PLA (Figure 3.10E), some discrepancy in quantification 
was observed in pre-fibrotic bone marrow of Gata-1low mice. For a validation of the 
PLA for PDGFRβ‒PDGF-B interaction analysis (see Figure 2.2B in the ‘Methods’ 
section for assay principle), data from a PLA was compared to colocalization data 
gathered from multispectral imaging (Figure 3.10F and G). The data acquired by PLA 
were generally in good agreement with data acquired by multiplex staining as another 
antibody-based method. However, colocalization and PLA interaction analyses rely 
on principally different detection mechanisms, and minor differences were to be 
expected when juxtaposing both methods. 
 
Figure 3.10: Continued on page 57. 
 
 




Figure 3.10: Multiplexed immunohistochemical (IHC) staining of platelet-derived growth factor (PDGF)-B and 
PDGF receptor β (PDGFRβ), and in situ protein quantification by imaging and by single recognition proximity 
ligation assay (PLA) in the bone marrow of Gata-1low mice at 5 months (5 M), 10 months (10 M) and 15 months 
(15 M) of age. A Representative images showing femoral bone marrow of Gata-1low mice and WT control mice 
stained for PDGFRβ (green) and PDGF-B (magenta). Nuclei were counterstained with DAPI (blue), scale bars 
= 50 µm. Images show the same sections which are depicted in Figure 3.7. B Quantification of PDGFRβ protein 
expression using the acquired imaging data. C Quantification of PDGFRβ protein expression using single 
recognition PLA. D Quantification of PDGF-B protein expression using the acquired imaging data. 
E Quantification of PDGF-B protein expression using single recognition PLA. F Quantification of PDGFRβ‒
PDGF-B colocalization using the acquired imaging data. G Quantification of PDGFRβ‒PDGF-B interaction using 
PLA. All quantification plots show exemplary data from one and the same mouse, respectively, per group. 
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After methodical validation, the single recognition PLA was applied to quantify protein 
expression of the PDGF signaling components within the mouse cohorts (Figure 3.11 
and Figure 3.12). Although a heterogeneity in protein expression was observed in 
Gata-1low mice, there was a steady increase in PDGF receptor protein expression 
during the development of myelofibrosis, whereas expression in WT mice remained 
steady (Figure 3.11). However, only increases in PDGFRα protein expression in pre-
fibrotic bone marrow (Figure 3.11C) and in PDGFRβ protein expression in overt 
fibrotic bone marrow (Figure 3.11D) reached statistical significance. When analyzing 
PDGF-A and PDGF-B protein expression by single recognition PLA, high 
heterogeneity among age-matched Gata-1low mice was observed (Figure 3.12). 
There was a particularly high signal strength when detecting PDGF-A protein 
expression by single recognition PLA (Figure 3.12A), still, there was no significant 
increase in PDGF-A expression in Gata-1low mice compared to WT controls (Figure 
3.12C). However, PDGF-B protein expression was significantly increased in overt 
fibrotic bone marrow of 15-month-old Gata-1low mice compared to WT animals 
(Figure 3.12B and D). 
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Figure 3.11: Protein expression of platelet-derived growth factor receptors (PDGFRs) in the bone marrow of 
Gata-1low mice at 5 months (5 M), 10 months (10 M) and 15 months (15 M) of age. Representative images of 
single recognition proximity ligation assay (PLA) approaches for analyses of A PDGFRα and B PDGFRβ protein 
expression in the bone marrow of Gata-1low mice and age-matched wild type (WT) controls. C Quantitative 
analyses of PDGFRα and D PDGFRβ protein expression by single recognition PLA. Scale bars = 20 µm, 
RCPs: rolling circle products.  
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Figure 3.12: Protein expression of platelet-derived growth factors (PDGFs) in the bone marrow of Gata-1low mice 
at 5 months (5 M), 10 months (10 M) and 15 months (15 M) of age. Representative images of single recognition 
proximity ligation assay (PLA) approaches for analyses of A PDGF-A and B PDGF-B protein expression in the 
bone marrow of Gata-1low mice and age-matched wild type (WT) controls. C Quantitative analyses of PDGF-A 
and D PDGF-B protein expression by single recognition PLA. Scale bars = 20 µm, RCPs: rolling circle products. 
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3.4 PDGFRβ‒ligand interaction and phosphorylation in the bone marrow 
Whereas megakaryocyte dysplasia and proliferation is a defining feature of PMF, 
fibroblast proliferation leading to a progressive fibrosis is the key pathological aspect 
of PMF. Given the distinct expression of PDGFRβ in stromal cells in early and overt 
fibrotic bone marrow, shown by multiplexed IHC (Figure 3.7 and Figure 3.8), this 
study further concentrated on the dynamics of PDGFRβ and its ligand PDGF-B. The 
increased protein expression of PDGFRβ and its ligand PDGF-B in overt 
myelofibrosis, analyzed by single recognition PLA (Figure 3.11 and Figure 3.12), 
prompted to investigate the interaction of both signaling components in situ. In order 
to analyze PDGFRβ‒PDGF B binding, a PLA using combined primary antibodies 
detecting PDGFRβ and PDGF-B was performed. PLA analyses of PDGFRβ‒PDGF-B 
interaction revealed an increased interaction of receptor and ligand in overt fibrotic 
bone marrow of 15-month-old Gata-1low mice (Figure 3.13A and C). This is in 
accordance with enhanced protein expression of both PDGFRβ and PDGF-B in overt 
fibrotic bone marrow of Gata-1low mice and also suggests an increased activation of 
intracellular signaling in the overt fibrotic stage. To further analyze the activation 
status of the receptor, a PLA combining PDGFRβ and phosphotyrosine-targeting 
primary antibodies was applied in order to analyze PDGFRβ phosphorylation in situ 
(see Figure 2.2C in the ‘Methods’ section for assay principle). Surprisingly, no 
increased PDGFRβ tyrosine phosphorylation was observed at any stage of 
myelofibrosis in Gata-1low mice (Figure 3.13B and D), suggesting the presence of 
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Figure 3.13: Analyses of platelet-derived growth factor receptor β (PDGFRβ) interaction with platelet-derived 
growth factor (PDGF)-B and PDGFRβ tyrosine phosphorylation in the bone marrow of Gata-1low mice and wild 
type (WT) controls at 5 months (5 M), 10 months (10 M) and 15 months (15 M) of age. Representative images 
showing a proximity ligation assay (PLA) for the analysis of A PDGFRβ–PDGF-B interaction and B PDGFRβ 
tyrosine phosphorylation in femoral bone marrow of Gata-1low mice and WT controls. C Quantitative analyses 
of PDGFRβ–PDGF-B interaction and D PDGFRβ tyrosine phosphorylation. Scale bars = 20 µm, RCPs: rolling 
circle products. 
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3.5 Expression of PTPs in the bone marrow 
PTPs represent key regulators of RTK phosphorylation and altered PTP expression 
can have profound effects on cellular function.207 Although the experiments within 
this study demonstrated increased protein expression, as well as interaction of 
PDGFRβ and PDGF-B, PDGFRβ phosphorylation was not enhanced. Therefore, 
differential gene expression of PTPs was examined using RNAseq data from early 
fibrotic bone marrow of Gata-1low mice (Figure 3.14). The majority of PTPs was not 
differentially regulated in this stage of bone marrow fibrosis, nevertheless, there was 




Figure 3.14: RNA sequencing analyses showing differential gene expression of protein tyrosine phosphatases 
(PTPs). Total RNA from femoral bone marrow of 10-month-old mice (n=3 Gata-1low vs. n=3 wild type mice) was 
analyzed. ns: not significant. 
Within these data, PDGFRβ-dephosphorylating PTPs were not differentially 
expressed (see Table 1.3 in the ‘Introduction’ section for a list of PDGFRβ-targeting 
PTPs). However, RNAseq data was only available from 10-month-old mice with n=3 
mice per group. For a more refined investigation of PDGFRβ-dephosphorylating 
PTPs, gene expression of the six classical, class I PTPs, which are known to target 
PDGFRβ, was analyzed by qPCR (Figure 3.15A-F). Very distinct expression 
dynamics among gene expression of Ptpn1 (encoding PTP1B), Ptpn2 (encoding 
TC-PTP), Ptpn6 (encoding SHP-1), Ptpn11 (encoding SHP-2), Ptpn12 (encoding 
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PTP-PEST) and Ptprj (encoding DEP-1) were observed. Overall, the data generated 
by qPCR from early fibrotic bone marrow of 10-month-old Gata-1low mice again 
displayed heterogeneity in gene expression, possibly contributing to the lack of 
significance within the RNAseq analyses from these mice. 
Interestingly, Ptpn1 and Ptprj gene expression, analyzed by qPCR, was 
downregulated in pre-fibrotic bone marrow, a phenomenon that has previously been 
observed for Col1a1, Pdgfrb and Pdgfa gene expression. Ptpn2, Ptpn6, Ptpn11 and 
Ptpn12 were not differentially expressed in pre-fibrotic bone marrow. However, all 
analyzed PTPs, measured by median, show tendencies towards an upregulation in 
early fibrotic bone marrow of 10-month-old Gata-1low mice. Still, only the increased 
expression of Ptpn11 and Ptpn12 reached significance. In overt fibrotic bone marrow, 
Ptpn1, Ptpn6, Ptpn12 and Ptprj gene expression was not different in Gata-1low mice 
and WT controls, but there was a significant increase in Ptpn2 and Ptpn11 gene 
expression in overt fibrotic bone marrow. 
 
 
Figure 3.15: Gene expression analyses of platelet-derived growth factor receptor β (PDGFRβ)-targeting protein 
tyrosine phosphatases (PTPs) in the bone marrow of Gata-1low mice and wild type (WT) controls at 5 months 
(5 M), 10 months (10 M) and 15 months (15 M) of age. qPCR analyses of A Ptpn1, B Ptpn2, C Ptpn6, D Ptpn11, 
E Ptpn12 and F Ptprj. 
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An increased PTP expression in the bone marrow of 15-month-old Gata-1low mice 
might be a possible explanation for previous observations regarding the lack of 
PDGFRβ phosphorylation in the overt fibrotic stage. Especially induction of Ptpn2, 
encoding T cell PTP (TC-PTP), was highly significant in overt fibrotic bone marrow. 
Given the conclusive increase in Ptpn2 gene expression and the vital role of TC-PTP 
in normal hematopoietic function,236,237 this study further focused on the role of 
TC-PTP as a possible contributor to PDGFRβ regulation.  
3.6 TC-PTP expression and interaction with PDGFRβ in the bone marrow 
In order to visualize and evaluate the expression patterns of TC-PTP in the bone 
marrow of Gata-1low mice, multiplexed IHC was used (Figure 3.16). Staining of 
TC-PTP (red) revealed ubiquitous expression in the bone marrow of both WT and 
Gata-1low mice of all ages. There was a slight but visible increase in TC-PTP staining 
intensity in the bone marrow of 10-month-old and 15-month-old Gata-1low mice.  
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Figure 3.16: Multiplexed immunohistochemical (IHC) staining of TC-PTP and platelet-derived growth factor β 
(PDGFRβ) in the bone marrow of Gata-1low mice at 5 months (5 M), 10 months (10 M) and 15 months (15 M) of 
age. Representative images showing femoral bone marrow of Gata-1low mice stained for TC-PTP (red) and 
PDGFRβ (green). Nuclei were counterstained with DAPI (blue), scale bars = 50 µm. Images show the same 
sections which are depicted in Figure 3.7. 
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The fact that TC-PTP is expressed in a variety of different cells in the bone marrow, 
as shown in Figure 3.16, further raised the question, if TC-PTP expression in 
fibroblasts potentially enables direct regulation of PDGFRβ by TC-PTP in fibrosis-
driving cells. Again, unmixed imaging data from multiplexed IHC were used to 
generate high magnification pseudo-brightfield IHC images from bone marrow 
sections of Gata-1low mice (Figure 3.17). These images accentuate ubiquitous 
expression of TC-PTP in the bone marrow, and further, TC-PTP positivity was 
detected in spindle-shaped cells which were likewise positive for PDGFRβ 
expression (black arrowheads). The validity of this finding is strengthened by direct 
comparison to expression patterns of PTP1B. PTP1B and TC-PTP are two tightly 
related class I PTPs and structurally highly homolog.238 Nonetheless, there is a 
striking difference in expression of these two PTPs in the bone marrow. PTP1B 
expression was virtually absent in spindle-shaped stromal cells and TC-PTP clearly 
discriminated as a potential regulatory PTP in bone marrow stromal cells. 
 
 
Figure 3.17: Pseudo-brightfield immunohistochemical (IHC) images of platelet-derived growth factor receptor β 
(PDGFRβ), TC-PTP and PTP1B. Positive staining in spindle-shaped stromal cells is indicated by black 
arrowhead. Scale bars = 20 µm. 
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Subsequently, TC-PTP protein expression was analyzed and quantified by single 
recognition PLA (Figure 3.18A). Quantitative analysis of confirmed an increased 
TC-PTP protein expression in early myelofibrosis (Figure 3.18C). The increased 
expression of PDGFRβ and TC-PTP in the bone marrow of Gata-1low mice and the 
immunohistochemical detection indicating expression of both proteins in the same 
cell type further raised the question, if there is a profound interaction of both 
components in fibrotic bone marrow. 
To analyze the interaction of PDGFRβ and TC-PTP, a PLA was applied using a 
combination of PDGFRβ and TC-PTP primary antibodies (see Figure 2.2D in the 
‘Methods’ section for assay principle). Interestingly, there indeed was an increased 
interaction of PDGFRβ and TC-PTP in early and overt fibrotic bone marrow of 
Gata-1low mice (Figure 3.18B and D). 
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Figure 3.18: Analyses of TC-PTP protein expression and interaction with platelet-derived growth factor 
receptor β (PDGFRβ) in the bone marrow of Gata-1low mice and wild type (WT) controls at 5 months (5 M), 
10 months (10 M) and 15 months (15 M) of age. Representative images showing a proximity ligation assay 
(PLA) for analyses of A TC-PTP protein expression B PDGFRβ–TC-PTP interaction in femoral bone marrow of 
Gata-1low mice and WT controls. C Quantitative analyses of TC-PTP protein expression and D PDGFRβ–
TC-PTP interaction. Scale bars = 20 µm, RCPs: rolling circle products. 
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3.7 TC-PTP expression in fibroblasts in vitro 
The findings of increased PDGFRβ and TC-PTP expression and interaction in bone 
marrow fibrosis led to further analyze the regulation of PDGFRβ by TC-PTP in 
fibroblasts. To enable functional analyses of both components, a murine fibroblast 
cell line (NIH-3T3 cells) was used for in vitro experiments. Expression of many 
proteins is influenced by cell-cell-contacts, a well-characterized example is the 
increased expression of the eponymous density-enhanced phosphatase 1 (DEP-1) 
in dense cells.239 Therefore, PDGFRβ and TC-PTP protein expression and PDGFRβ 
tyrosine phosphorylation was investigated in different cell densities (Figure 3.19A). 
There was no difference in protein expression of PDGFRβ and TC-PTP in 40% vs. 
100% confluent NIH-3T3 cells (Figure 3.19B and C). However, activation of PDGFRβ 
by PDGF-BB was decreased in dense cells (Figure 3.19D), but without significant 
























































Figure 3.19: Effect of cell density on platelet-derived growth factor receptor β (PDGFRβ) activation in NIH-3T3 
cells. Immunoblot of 40% and 100% confluent cells, untreated (–) and stimulated with 50 ng/ml PDGF-BB (+) 
for 5 min. B Densitometric analyses of PDGFRβ, C TC-PTP, D pPDGFRβ Y751 and E pAKT S473. 
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These cell density-dependent differences in activation of PDGFRβ emphasize the 
importance of ensuring consistent growth statuses among different experiments and 
hence, all subsequent experiments were performed using equivalent cell densities 
(50-60%). 
3.8 TC-PTP in PDGFRβ signaling and proliferation in vitro 
To investigate the regulation of PDGFRβ by TC-PTP, Ptpn2 expression was knocked 
down in NIH-3T3 fibroblasts (Figure 3.20A). Transfection with Ptpn2-targeting siRNA 
resulted in a moderate but significant knockdown compared to cells transfected with 
nontargeting siRNA (100% TC-PTP protein expression relative to GAPDH in 
nontargeting control cells vs. 61.2% relative TC-PTP protein expression in Ptpn2 
knockdown cells, Figure 3.20B). Cells were stimulated with PDGF-BB, leading to 
PDGFRβ tyrosine phosphorylation and activation of downstream signaling pathways 
such as AKT, ERK and PLCγ1 signaling. Ptpn2 knockdown increased PDGF-BB-
mediated PDGFRβ phosphorylation at tyrosine sites Y751 and Y1021, signifying 
PDGFRβ dephosphorylation by TC-PTP at both sites (Figure 3.20C and D). 
Consecutive to increased PDGFRβ phosphorylation at Y751, increased downstream 
AKT signaling was observed in Ptpn2 knockdown cells (Figure 3.20E). However, 
there was no substantial effect on downstream ERK signaling (Figure 3.20F). In 
accordance with enhanced PDGFRβ phosphorylation at Y1021, downstream PLCγ1 
activation was increased in Ptpn2 knockdown cells (Figure 3.20G). 
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Figure 3.20: Regulation of platelet-derived growth factor receptor β (PDGFRβ) signaling by TC-PTP in NIH-3T3 
cells. A Immunoblot of Ptpn2 knockdown (KD) and nontargeting (NT) control cells, untreated (–) and stimulated 
with 50 ng/ml PDGF-BB (+) for 5 min. B Densitometric analyses of TC-PTP, C pPDGFRβ Y751, D pPDGFRβ 
Y1021, E pPLCγ1 Y783, F pAKT S473, G pERK1/2 T202/Y204. 
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An increased activation of signaling pathways which are typically implicated in cell 
survival and proliferation was observed in Ptpn2 knockdown cells. Hence, 
proliferation of Ptpn2 knockdown cells subjected to different growth conditions was 
analyzed (Figure 3.21). Interestingly, monitoring cells for 6 days did not reveal 
evident differences in proliferation of cells cultured in complete growth medium 
containing 10% FBS. However, when cells were exposed to serum-reduced medium 
(1% FBS), Ptpn2 knockdown cells showed increased growth rates compared to 
control cells. Whereas control cells reached a maximum confluence of 60.6% in 
medium with 1% FBS, Ptpn2 knockdown cells reached 74.9% confluence and 
maintained higher cell densities in serum-reduced medium. 
 
 
Figure 3.21: Proliferation of Ptpn2 knockdown (KD) and nontareting (NT) control cells. Proliferation curves of 
NIH-3T3 cells cultured in medium containing 1% and 10% fetal bovine serum (FBS). 
 
Finally, elaborating on the interaction of both proteins within cells, the subcellular 
location of PDGFRβ and TC-PTP in fibroblasts was investigated by 
immunofluorescent staining of PDGFRβ and TC-PTP (Figure 3.22). As a 
transmembrane RTK, PDGFRβ (green) localized mainly to the plasma membrane as 
well as to endosomal vesicles in proximity to the nucleus, whereas TC-PTP (red) 
located to nucleus and cytoplasm. 
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Figure 3.22: Immunofluorescence (IF) staining of platelet-derived growth factor receptor β (PDGFRβ, green) 
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4 DISCUSSION 
Among the classical, BCR-ABL-negative MPNs, PMF is the most fatal disease with 
eminently unfavorable prognosis.240 There have been intensive efforts to understand 
the mechanisms leading to PMF, largely focusing on genetic analyses. However, the 
PMF-associated driver mutations (JAK2, CALR and MPL), which lead to aberrant 
activation of JAK-STAT signaling, are not unique for PMF but also occur in the other 
two classical, BCR-ABL-negative MPNs (ET and PV). There is currently no distinct 
molecular marker available for these MPNs, emphasizing that the underlying 
mechanisms directing the different MPNs are not yet completely understood, and 
pointing towards the need for further diagnostic tools. 
In this study, detailed analyses of the expression patterns of PDGFRβ signaling 
components in a mouse model for PMF at different fibrotic disease stages was 
provided using RNAseq, qPCR, multiplexed IHC, as well as in situ protein expression 
and interaction analyses by PLA. Early and overt fibrotic bone marrow was 
characterized by significant upregulation of PDGF signaling components and overt 
fibrosis by an increase in PDGFRβ–PDGF-B interaction. Since PDGFRβ tyrosine 
phosphorylation levels were not elevated, the regulation of PDGFRβ by counter-
acting PTPs was investigated. In particular, Ptpn2 gene as well as TC-PTP protein 
expression was increased in overt fibrotic bone marrow of Gata-1low mice. 
Furthermore, enhanced PDGFRβ–TC-PTP interaction was observed in early and 
overt myelofibrosis, presumably counteracting PDGFRβ phosphorylation. Likewise, 
Ptpn2 knockdown increased PDGFRβ tyrosine phosphorylation at Y751 and Y1021, and 
resulted in enhanced downstream AKT and PLCγ1 signaling in fibroblasts. Finally, 
Ptpn2 knockdown cells showed a growth condition-dependent increase in cell 
expansion rate.  
4.1 Mouse models for myelofibrosis 
PMF progression is marked by thrombocytopenia, the presence of dysplastic 
megakaryocytes and proliferation of fibroblasts with excessive production of ECM in 
the bone marrow of patients. To elucidate mechanisms of PMF, there have been 
different approaches to mimic the disease in mouse models. The number of 
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megakaryocytes can e.g. be raised by altering thrombopoietin levels in mice.241-243 
Thrombopoietin controls megakaryopoiesis244 and increased levels of 
thrombopoietin lead to a quick development of myelofibrosis in mice within 2 to 
3 months.242 Other mouse models employ the mutations which can frequently be 
found in PMF patients. However, mice harboring the most commonly occurring 
JAK2V617F mutation develop a PV phenotype, which does not evolve into 
myelofibrosis.245 In contrast, mice with a calreticulin mutation that can frequently be 
detected in PMF patients, show symptoms of ET.246 In the mutant CALR model, 
heterozygous mice, in contrast to homozygous mice, do not develop myelofibrosis. 
The phenotype in homozygous mice, however, recapitulates a secondary 
myelofibrosis. The most common human mutation in the thrombopoietin receptor 
(MPLW515L) induced a myeloproliferative phenotype in murine bone marrow transplant 
assays with a rapid development of myelofibrosis, however, mice died between 17 
and 32 days after transplantation.72 Thus, these mouse models display discrepancies 
to human PMF and partly resemble features of the other classical, BCR-ABL-
negative MPNs. 
GATA-1, encoded by the X-chromosomal GATA1 gene, is a transcription factor that 
plays a crucial role in differentiation of various hematopoietic lineages such as in 
erythroid and megakaryocytic differentiation.247 Although GATA1 is not mutated in 
PMF patients, megakaryocytes of PMF patients show decreased GATA-1 
expression.235 The reasons for this have not been elucidated yet, although it is 
hypothesized that reduced GATA-1 expression is a consequence of ribosomal 
deficiency as a result of increased JAK-STAT signaling.248 Gata1 knockout mice die 
in utero due to severe anemia.249,250 Gata-1low mice were originally generated by a 
deletion in the upstream promotor region of the murine Gata1 gene in C57Bl/6 mice, 
however, mice showed high mortality around birth.251,252 When those mice were 
backcrossed to CD1 mice, viability greatly improved.229 This suggests an important 
contribution of the genetic background to disease phenotype. Gata-1low mice show 
decreased expression of Gata-1 in megakaryocytes, thrombocytopenia and develop 
myelofibrosis in a time span of 2 years.230 Importantly, Gata-1low mice do not feature 
ET of PV symptoms and the slow disease progression resembles the development 
of a chronic disease in patients, and therefore Gata-1low mice are suitable for the 
study of PMF development in mice.  
4  DISCUSSION  78 
 
4.2 Development of myelofibrosis in Gata-1low mice 
This study aimed at characterizing Gata-1low mice at different stages of disease 
development and hence mice were analyzed at 5, 10 and 15 months of age. 
A marked thrombocytopenia and splenomegaly was observed in mice of all analyzed 
ages. Further, mice displayed a mild, but progressive leukocytosis and progressive 
anemia. A high number of dysplastic megakaryocytes was present in the bone 
marrow of Gata-1low mice, and starting from 10 months of age, reticulum fibers 
accumulated in the bone marrow. At 15 months of age, there was a pronounced 
fibrosis in the bone marrow of Gata-1low mice. Hence, Gata-1low mice recapitulate the 
key features of disease development as seen in PMF patients. Interestingly, an 
impaired survival in female, homozygous Gata-1low mice was observed. Other studies 
using the Gata-1low mouse model did not report any sex-specific differences during 
the onset of myelofibrosis, however, the increased mortality of homozygous females 
in this study suggests a harsher phenotype in females. Indeed, it must be noted that 
mutation in the Gata1 promotor region is X-linked. Hence, hematological parameters 
of male and female mice were compared in this study to reveal potential sex-specific 
discrepancies. Nevertheless, the small number of available female, homozygous 
Gata-1low mice weakened plausibility of statistical analyses, and for female Gata-1low 
mice at 15 months of age (n=1), statistical analysis was not applicable. However, 
there were slight differences in red blood cell counts of both sexes in 10-month-old 
Gata-1low mice and 15-month-old WT mice, as well as in white blood cell and platelet 
counts in 15-month-old WT mice. Thus, in addition to potential differences in disease 
progression in female Gata-1low mice, the sex-specific discrepancies in WT mice 
suggest age-dependent differences in hematological parameters in male and female 
mice. Conclusively, to reduce heterogeneity in this age-dependent study, male mice 
were used for experiments. In regard to sex-specific differences in PMF disease 
progression, patients do not resemble the same gender-specific discrepancies seen 
in the Gata-1low mouse model. Although decreased GATA-1 expression can also be 
observed in PMF patients, a model using an X-linked mutation is substantially 
different in its underlying disease-inducing mechanism compared to the PMF-
initiating mutations in JAK2, CALR or MPL. Interestingly, PMF is slightly more 
prevalent in men than in women,51 without knowledge on the underlying causes for 
this difference. 
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4.3 Transcriptomic alterations in myelofibrosis 
The transcription analyses in early fibrotic bone marrow of Gata-1low mice revealed 
1503 up-, and 1604 downregulated genes. Among the different RTKs, a general trend 
towards an upregulation was observed. This is in line with the established role of 
many RTKs in proliferative and cancerous diseases.253 However, among the ligands 
for those RTKs, many genes were not differentially regulated. Given the hypothesis 
of an increased production of cytokines and growth factors in the bone marrow of 
PMF patients, which in the literature is often referred to as a ‘cytokine 
storm’,56,76,254,255 it seems rather surprising not to find a more striking increase in 
gene expression of those ligands. Nevertheless, this highlights the importance of 
RTKs as well as other components contributing to the tightly orchestrated regulation 
of signaling components. 
GO enrichment analyses further revealed that genes implicated in PDGF binding 
were most overrepresented within the 1503 upregulated genes in the bone marrow 
of 10-month-old Gata-1low mice. Given the implication of the PDGF system in the 
development of myelofibrosis and the lack of information about the role of PDGF 
signaling dynamics in pre-fibrotic stages, this study further aimed at characterizing 
the PDGF signaling components in the different stages of myelofibrosis. 
4.4 PDGF signaling components in bone marrow fibrosis 
The data in this study showed an induction in gene expression of PDGF receptors 
and ligands in the bone marrow of Gata-1low mice at 10 months of age. Interestingly, 
collagen gene expression in the bone marrow of Gata-1low mice was highest in an 
early fibrotic stage. Hence, there was an evident overlap of the induction of PDGF 
signaling components with a major increase in collagen type I and type III gene 
expression during the early stage of bone marrow fibrosis. Collagen and PDGF 
signaling component gene expression remained enhanced in overt fibrotic bone 
marrow, although less pronounced compared to early fibrotic bone marrow of 
Gata-1low mice, showing that collagen expression and PDGF signaling are clearly 
concurrent events. This is in agreement with the fact that collagens bind PDGF-A 
and -B homo- and heterodimers, and modulate stability and long-term activation of 
4  DISCUSSION  80 
 
the ligands, thus enhancing mitogenic activity.256 Vice versa, however, PDGF-A and 
-B homo- and heterodimers do not stimulate the production of collagens in fibroblasts 
in vitro, although effects on collagen gene expression seem to be highly dose-
dependent.257,258 
At protein level, a steady increase in both PDGFRα and PDGFRβ protein expression 
was observed during the development of myelofibrosis, whereas expression in WT 
mice remained steady. A significantly enhanced PDGFRβ protein expression was 
detected in Gata-1low mice at 15 month-of-age. There was no increase in PDGF-A 
expression, but PDGF-B protein expression was increased in overt fibrotic bone 
marrow of 15-month-old Gata-1low mice compared to WT controls. 
Within this study, multiplexed IHC was further used to evaluate cell-specific 
expression of PDGF receptors and ligands. There was a pronounced expression of 
PDGF-A, -B and PDGFRα in megakaryocytes, whereas PDGFRβ expression was 
absent in megakaryocytes. PDGFRβ was mainly expressed in long and spindle-like 
cells with elongated nuclei, which represent bone marrow stromal cells. The primary 
antibodies used for immunohistochemical detection in this study are specific for the 
different PDGF ligand and receptor isoforms, still, those antibodies detect peptide 
sequences within protein monomers. PDGF ligands are synthesized as dimers 
(PDGF-AA and -BB homo, and PDGF-AB heterodimers, see Figure 1.3 in the 
‘Introduction’) and, physiologically, do not exist as functional monomers.109-113 PDGF 
receptors, which are transmembrane RTKs, reside in the plasma membrane and 
dimerize upon ligand binding.116,128 Hence, the antibody-based methods in this study 
might detect homo- as well as heterodimers. Since both PDGF-A and -B were located 
to megakaryocytes, those ligands can very well be present as PDGF-AA and -BB 
homo-, and PDGF-AB heterodimers. Since PDGFRα expression was limited to 
megakaryocytes and PDGFRβ expression to stromal cells, it can be reasoned that 
PDGFRαβ heterodimers do not play a measurable role in the pathology of bone 
marrow fibrosis. Conclusively, PDGFRα signals mainly through PDGFRαα 
homodimers in megakaryocytes. Localization data further indicates that PDGF-AA 
exerts its effects on PDGFRαα in an autocrine manner from megakaryocytes, but 
also in paracrine fashion from other hematopoietic cells in the bone marrow which 
evidently expressed PDGF-A. Still, activation of PDGFRαα by megakaryocyte-
derived PDGF-AB heterodimers might also play a role. An increase in PDGFRα 
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expression in megakaryocytes is particularly interesting, since it is emerging in HSC-
derived, clonal cells. In contrast to Gata-1low mice, these cells are typically harboring 
one of three driver mutations (JAK2, CALR or MPL) in PMF patients. Despite the 
differences in the mouse model, where HSCs do not harbor any of these driver 
mutations, PDGFRα expression is indeed increased in the bone marrow of PMF 
patients.89 It is therefore highly interesting that, as recently published, PDGF-AA and 
-BB production is not decreased after treatment with ruxolitinib in an MPN mouse 
model. Further, PDGFRα signaling remained active despite JAK1/2 inhibition by 
ruxolitinib.103 
In this study, PDGF-B expression was detected in megakaryocytes and 
consequently, PDGF-BB signals on PDGFRββ homodimers, expressed in bone 
marrow fibroblasts, in a paracrine manner. In contrast to PDGFRαα, PDGFRββ is not 
activated by PDGF-AB heterodimers (see Figure 1.3 in the ‘Introduction’). The data 
generated within this study therefore strongly supports the notion that paracrine 
signaling of PDGF-BB on PDGFRββ drives fibroblast proliferation in bone marrow 
fibrosis. Hence, this study further placed special focus on these PDGF ligand and 
receptor isoforms. 
It has previously been described that PDGFRβ expression in PMF bone marrow 
fibroblasts correlates with the grade of myelofibrosis and that immunohistochemical 
staining of PDGFRβ in bone marrow of PMF patients might serve as a marker for 
PMF progression.90,187,188 It should further be noted that selective inhibition of 
PDGFRβ in PMF patients might still be a promising treatment option. Inhibition of 
PDGFRβ by imatinib has been largely dismissed after marginal effects in three 
different studies.193-195 However, none of the patients within these small scale studies 
(11 - 23 PMF patients) have been selected for enhanced PDGFRβ expression in the 
bone marrow, and a subset of patients could benefit from PDGFRβ inhibition. The 
gradual increase of PDGFRβ protein expression, which can be observed in PMF 
patients, was also present in Gata-1low mice. Thus, the data generated within this 
study are supportive of the findings in PMF patients. Henceforth, PDGFRβ 
expression during PMF development in mice was investigated in-depth using 
sophisticated and sensitive methods. 
Yet, insights into whether PDGFRβ expression is upregulated at a transcriptional 
level in these cells or if increased PDGFRβ expression is a result of an increased 
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number of fibroblasts in fibrotic bone marrow are still lacking and should be further 
investigated. While the latter seems straightforward, it is reasonable that fibroblasts 
and other stromal cells in PMF display altered function and expression patterns. 
Fibroblasts in PMF are not considered malignant, since they do not harbor driver 
mutations.49 This rationale is strongly supported by the fact, that allogenic stem cell 
transplantation, and thus elimination of the clonal HSC population, is curative for 
PMF and can reverse fibrosis.259 Nevertheless, fibroblasts in PMF can feature other 
genetic abberations,260 and chronic inflammation and a dysfunctional 
microenvironment can effect expression of PDGF signaling components.185 Hence, 
transcriptional, translational or epigenetic alterations are conceivable in PMF 
fibroblasts. Experiments using induced pluripotent stem cells further show that 
PDGFRβ expression underlies epigenetic regulation by DNA methylation, and that 
the PDGFRβ-associated methylation landscape largely changes after 
differentiation.261 Moreover, surface levels of PDGFRβ can be altered by recycling 
and degradation mechanisms. PDGF receptors are internalized upon ligand binding 
and then recycled to the plasma membrane, or ubiquitinated and degraded.200 The 
phosphatase TC-PTP, for example, does not only alter PDGFRβ function by 
dephosphorylation, but also influences intracellular trafficking and degradation, 
directing PDGFRβ towards Rab4-dependent recycling pathways.262 This is especially 
interesting in the context of increased TC-PTP expression and PDGFRβ‒TC-PTP 
interaction observed in this study. 
4.5 Activation and regulation of PDGFRβ in myelofibrosis 
Along with an increase in PDGFRβ and PDGF-B protein expression, an increase in 
PDGFRβ–PDGF-B interaction was observed in overt fibrotic bone marrow of 
Gata-1low mice, analyzed by PLA. This finding seems self-evident, given the 
increased protein expression in this stage of the disease. When analyzing PDGFRβ 
tyrosine phosphorylation, however, no increase was detected. There are a number 
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a) PDGFRβ tyrosine phosphorylation is a rare event 
Tyrosine phosphorylation is a rare event. The ratio of phosphorylated serine, 
threonine vs. phosphorylated tyrosine residues are approximately 90%, 10% vs. 
0.05% in the overall cellular phosphoproteom.263,264 Furthermore, PDGFRβ is a 
relatively low abundant receptor. Differences in PDGFRβ tyrosine phosphorylation 
state might be subtle. Other detection methods (e.g. IB) use an amplified signal (e.g. 
enhanced chemiluminescence), which can be used to visualize phosphorylated 
tyrosine residues in blotted proteins. The PLA creates one signal per accessible 
PDGFRβ tyrosine phosphorylation site, and formalin-fixed, paraffin-embedded tissue 
presents a thin section of a respective tissue. In 1 µm bone marrow sections, the 
overall number of signals might not be sufficient to display subtle differences in 
phosphorylation states. However, the high cellularity of hematopoietic cells, which 
typically have a rather small proportion of cytoplasmic area but are comprised mostly 
of nucleus, did not allow for the use of thicker sections, otherwise cells would not 
have been microscopically distinguishable. 
b) Methodology 
In the wider context of a), the detection of PDGFRβ tyrosine phosphorylation might 
further be impeded by the accessibility of antibody epitopes. According to 
manufacturer’s information, the monoclonal PDGFRβ antibody used (Y92) 
recognizes an epitope between amino acid position 1050 and the C-terminus. There 
are no tyrosine residues within this part of the sequence and hence, binding of this 
antibody to the receptor should a priori not interfere with the binding of 
phosphotyrosine-targeting antibodies. However, it cannot be ruled out that specific 
conformation and tertiary structure might influence detection of certain 
phosphorylation sites. In order to address this issue, three widely used 
phosphotyrosine-targeting antibodies were used (pY100, pY20 and 4G10) in 
combination with the PDGFRβ antibody. Although it is generally assumed that these 
antibodies bind phosphotyrosine residues rather unspecifically, there is evidence that 
they differ in their sequence preference.265 Therefore, a combination of these three 
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c) Physiological situation is not unambiguous 
Tyrosine phosphorylation in cells within tissues is not a straightforward event, 
especially compared to in vitro experiments. Under physiological conditions, the 
simplified but artificial switch-off (unstimulated, unphosphorylated) and switch-on 
(stimulated, phosphorylated) does not exist in such an unambiguous, mutually 
exclusive manner. 
d) Upregulation of PTPs 
Receptor phosphorylation is tightly regulated by presence of PTPs, which 
dephosphorylate PDGFRβ. A number of PTPs, which site-selectively 
dephosphorylate PDGFRβ, have previously been identified: PTP1B,118,211-213 
TC-PTP,212,214 SHP-1,215,216 SHP-2,212,217-221 PTP-PEST,212,222 DEP-1,223 PTEN224 
and LMW-PTP.225 An increased expression of these PTPs might be responsible for 
the absence of an increased PDGFRβ phosphorylation. Using RNAseq data from 
early fibrotic bone marrow of Gata-1low mice, PTPs were analyzed for differential 
expression and it was observed that the majority of PTPs was not differentially 
regulated in this stage of bone marrow fibrosis. The above mentioned, PDGFRβ-
dephosphorylating PTPs were not differentially expressed within the RNAseq data. 
To overcome drawbacks by small numbers of mice analyzed by RNAseq, and to 
include all three disease stages in the analyses, gene expression of the six classical, 
class I PTPs, which are known to target PDGFRβ, was analyzed by qPCR. The 
results showed different expression dynamics among gene expression of Ptpn1 
(encoding PTP1B), Ptpn2 (encoding TC-PTP), Ptpn6 (encoding SHP-1), Ptpn11 
(encoding SHP-2), Ptpn12 (encoding PTP-PEST) and Ptprj (encoding DEP-1). 
Interestingly, all analyzed PTPs showed tendencies towards an upregulation in early 
fibrotic bone marrow of 10-month-old Gata-1low mice, supporting the hypothesis that 
increased PTP expression contributes to PDGFRβ dephosphorylation. Only Ptpn2 
and Ptpn11 gene expression remained increased in overt fibrotic bone marrow. This 
study further focused on Ptpn2 (TC-PTP), since the increased Ptpn2 gene 
expression could conclusively explain the previously described results. Importantly, 
there are several lines of evidence showing an implication of TC-PTP in a number of 
bone marrow alterations (discussed more in detail in section 4.6).236,237,266,267 
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4.6 A potential role of TC-PTP in bone marrow fibrosis 
Ptpn2 gene expression, as well as TC-PTP protein expression was increased in overt 
fibrotic bone marrow of Gata-1low mice. As TC-PTP is ubiquitously expressed, 
PDGFRβ regulation by TC-PTP might play an important role in myelofibrosis. The 
multiplexed imaging of TC-PTP and PDGFRβ showed expression of both proteins in 
stromal cells, and indeed, an increased PDGFRβ–TC-PTP interaction in early and 
overt fibrotic bone marrow was detected by PLA. 
TC-PTP, which was first identified in a T cell cDNA library,268 is closely related to 
PTP1B. Both PTPs share 54% sequence identity, and even 69% in their PTP domain 
(sequences collected from UniProt database and aligned using NCBI blastp® tool). 
Due to a splicing site in the Ptpn2 gene, the primary transcript is spliced and can give 
rise to two TC-PTP isoforms. Both isoforms differ in their C-terminal part, isoform 1 
contains a hydrophobic ER-anchoring sequence, whereas isoform 2 contains a 
nuclear localization signal.269-271 Hence, isoform 1, a 48 kDa protein, is predicted to 
be located primarily to the ER, whereas isoform 2, a 45 kDa protein and more 
abundant than isoform 1, can shuttle between cytoplasm and nucleus.272 There has 
been evidence that TC-PTP isoform 1 dephosphorylates several RTK precursor 
proteins during their synthesis in the ER, e.g. the epidermal growth factor receptor 
(EGFR) and the adapter protein Shc.273,274 Possibly, TC-PTP supports proper protein 
processing by counteracting the autophosphorylation of RTKs during synthesis and 
posttranslational modification. In addition, TC-PTP dephosphorylates JAK-STAT 
signaling components,275 colony-stimulating factor 1 receptor (CSF1R)276 and 
PDGFRβ.212,214 
Homozygous TC-PTP knockout mice die 3 to 5 weeks after birth and display severe 
defects in hematopoiesis.237 Those defects were present mainly in erythropoiesis, 
and in T and B cell development, whereas myeloid and macrophage development 
were not impaired. Interestingly, transplantation of WT HSCs into lethally irradiated 
TC-PTP knockout did not rescue hematopoiesis. Vice versa, transplantation of 
TC-PTP knockout HSCs into WT mice did not result in comparable hematopoietic 
defects.237 This indicates that TC-PTP knockout leads to changes in the bone marrow 
microenvironment which prevents normal HSC function. In line with this, the number 
of stromal cells in the bone marrow of TC-PTP knockout mice was reduced when 
4  DISCUSSION  86 
 
compared to WT control mice.237 This is highly interesting in the context of the 
findings in this study, which provided evidence for the expression of TC-PTP in bone 
marrow stromal cells in myelofibrosis and the interaction with PDGFRβ. 
In accordance with predicted subcellular location of the two TC-PTP isoforms, 
TC-PTP expression was observed in nucleus and cytoplasm, as shown by 
immunofluorescence staining in NIH-3T3 fibroblasts. Neither PDGFRβ nor TC-PTP 
protein expression was influenced by cell density, but PDGFRβ tyrosine 
phosphorylation was reduced in dense fibroblasts in vitro. Ptpn2 expression was 
knocked down in NIH-3T3 fibroblasts and cells were stimulated with PDGF-BB. 
Consistent with other studies,212,214 IB analyses showed a counter-regulation of 
PDGFRβ by TC-PTP in fibroblasts in vitro. In contrast to a study suggesting that 
TC-PTP preferentially dephosphorylates PDGFRβ Y1021 site,214 however, a greater 
effect of Ptpn2 knockdown on phosphorylation at Y751 was observed in this study, 
suggesting cell-type specific dephosphorylation patterns of TC-PTP. Ptpn2 
knockdown resulted in increased PDGFRβ phosphorylation at Y751, which serves as 
a binding site for PI3K.134 Conclusively, an increase in downstream AKT activation 
as a central mediator of cell proliferation was detected. PDGFRβ phosphorylation 
also activates Ras and downstream ERK signaling,135 however, there was no 
increase in ERK signaling in Ptpn2 knockdown cells. The fact that PDGFRβ-mediated 
PI3K activation negatively regulates the ERK signaling might be a plausible 
explanation for this finding.141 Ptpn2 knockdown further led to increased PDGFRβ 
tyrosine phosphorylation at Y1021, resulting in enhanced downstream PLCγ1 
activation, suggesting a possible role of downstream protein kinase C and Ca2+ 
signaling.  
Ptpn2 knockdown fibroblasts cultured in complete growth medium containing 10% 
FBS did not have an apparent superiority in proliferation. However, increased growth 
rates in Ptpn2 knockdown cells exposed to reduced-serum media containing 1% FBS 
were detected. This suggests that under conditions of high abundance of growth 
factors, differences in proliferation in Ptpn2 knockdown cells are abolished, while 
apparent during serum-deprivation, possibly being closer to actual circumstances in 
the bone marrow. Other studies using murine skin cancer models showed that 
TC-PTP controls proliferation and survival via AKT and STAT3 activation.277,278 
Further, emphasizing the role of TC-PTP in hematopoietic cells, TC-PTP controls 
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T cell proliferation.266 The data in this study, based on a moderate knockdown, 
indicate that more discrete changes in TC-PTP expression controls cell growth 
mainly when the availability of growth components is limited. Furthermore, AKT and 
PLCγ1 were identified as contributing pathways. 
4.7 Methodology - considerations and limitations 
Diagnosis of PMF largely relies on histopathological assessment of bone marrow 
sections. Nevertheless, reproducibly in the evaluation of megakaryocyte morphology, 
which is essential to discriminate pre-PMF from ET, is modest among 
hematopathologists.58 The limitations in diagnostics and the lack of a specific 
molecular marker for PMF underlines the need for new molecular markers and 
diagnostic approaches. Within this study, multiplexed IHC and an in situ PLA were 
applied as sensitive means to analyze protein expression, interaction and 
phosphorylation. To our knowledge, this is the first study that utilized multiplexed IHC 
and PLA in bone marrow tissue. 
The bone marrow consists of a great number of different cell types in a strictly 
organized microenvironment. PMF is an excellent example for a disease, where it is 
essential to understand the cellular responses of different cell populations. Other 
widely used methods to phenotype and quantify cell populations, such as 
fluorescence-activated cell sorting (FACS) rarely reflect the physiological situation 
and hence, in situ analyses can provide helpful information. Further, even when 
analyzing cell populations deriving from the same clone in vitro, there can often be 
striking differences in protein expression between single cells. Widely used gene 
(i.e. RNAseq and qPCR) and protein expression analyses (i.e. IB) are population-
averaging methods, but useful information can get lost when cell-to-cell variations 
are masked.279,280 
PLA is an assay that is based on dual antibody recognition and local signal 
amplification when the two used antibodies are in close proximity. The method was 
first described in 2002,281 and later applied for in situ interaction analyses282 and to 
detect protein phosphorylation.283 Applied in a single recognition approach, PLA can 
visualize single molecules using microscopy.284 This is especially useful when 
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detecting low abundant proteins and within this study, single recognition PLA was 
used to quantify protein expression of PDGFs and their receptors. 
This method has definite advantages; it is a highly sensitive and quantitative method, 
relatively inexpensive and does not require special equipment. Furthermore, PLA is 
the only method which is applicable to analyze protein-protein interactions and 
posttranslational modifications in situ, whereas immunoprecipitation and IB are per 
se population-averaging approaches. The main limitation of the method is the need 
for tissue fixation, which can have effects on epitope integrity. In bone marrow tissue, 
processing includes decalcification of the bone to make the tissue applicable for 
sectioning. In this study, decalcification by EDTA was used as a mild approach to 
keep epitopes largely intact. However, in routine pathology, bone marrow biopsies 
are decalcified using acidic solutions. Furthermore, archiving conditions might 
contribute to epitope integrity.285 Finally, antibodies used for an in situ PLA must be 
specific, suitable for formalin-fixed samples, and for combination the antibodies must 
be raised in different species. Particularly in bone marrow tissue, fluorescent signals 
which are distinct from the clearly recognizable RCPs were observed during data 
generation in this study. These are most likely not ascribed to primary antibody 
binding but are caused by binding of the oligonucleotides which are conjugated to 
secondary antibodies (PLA probes). Such signals have also been observed using 
DNA probes in fluorescence in situ hybridization (FISH) approaches in bone marrow 
tissue and are associated with eosinophils.286 Although these signals are clearly 
disguisable in size and shape, and hence did not affect quantification, they could 
impact PLA eligibility in tissues which are rich in eosinophils. 
In conclusion, the use of PLA as a diagnostic approach to detect bone marrow 
alterations needs further optimization and must be individually adapted for the 
detection of defined and well-established markers. Nevertheless, sensitive in situ 
detection of interacting proteins or the activation status of receptors 
(e.g. phosphorylation) is highly interesting in diseases, which classically rely on 
utilization of histopathological methods. Further, monitoring of activation statuses is 
an interesting means to monitor disease progression and response to targeted 
therapies as a ‘companion diagnostics’ tool. 
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4.8 Perspectives of PTPs in the context of primary myelofibrosis 
Early diagnosis of pre-PMF is challenging due to its similarity to ET, nevertheless, 
correct distinction of both MPNs is clinically highly relevant.57 To date, the precise 
mechanisms causing myelofibrosis in PMF patients have still not been fully 
elucidated. The discovery of JAK-STAT-associated mutations led to the development 
of JAK inhibitors and since its FDA approval in 2011, the JAK1/2 inhibitor ruxolitinib 
has become part of combined standard therapy for PMF patients. Long-term 
treatment with ruxolitinib reduces spleen size and prolongs the overall survival of 
PMF patients.100 However, there is no improvement or reversal of bone marrow 
fibrosis, efficacy of ruxolitinib is limited by drug resistances,101 and JAK inhibition 
does not abrogate clonal proliferation.102 To date, allogeneic stem cell transplantation 
remains the only curative treatment for PMF, however, transplantation is only suitable 
for a subset of high-risk patients and limited by comorbidities and donor 
availability.96,97 The limitations in diagnosis and efficient treatment of PMF in 
particular emphasize the need for: 
(1) new molecular markers for an early diagnosis 
(2) new therapeutic approaches 
Referring to (1), it is highly relevant that the gene expression data generated in this 
study show very distinct expression patterns among the different PTPs during the 
development of PMF in mice. Expression of all analyzed PTPs showed trends 
towards an upregulation in early fibrotic bone marrow, although high biological 
variance diminished statistical significance in most cases. These data nonetheless 
indicate a clear implication of PTPs in early bone marrow fibrosis in mice. Indeed, a 
number of PTPs are associated with different types of human diseases, and several 
PTPs have previously been implicated in cancer. For instance, the class I dual-
specific phosphatase PTEN has a well-established role as a tumor suppressor and 
is mutated in different cancers, such as breast and prostate cancer.287 Furthermore, 
SHP-2 has been ascribed a pivotal role in many cancer types, e.g. breast, lung, liver, 
gastric cancer and leukemia.288 Another noteworthy example is PTPN13, which has 
emerged as a potential tumor suppressor in non-small cell lung cancer.289 
Prospectively, differentially expressed PTPs might be potential molecular markers 
with ability to facilitate early diagnosis of PMF. In this study, Ptpn1 (encoding PTP1B) 
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and Ptprj (encoding DEP-1) gene expression were downregulated in pre-fibrotic bone 
marrow of 5-month-old Gata-1low mice. In a stage where a commencing fibrosis can 
be detected in the bone marrow of Gata-1low mice at 10 months of age, both genes, 
reversely, showed tendencies of increased gene expression. It would be highly 
interesting if these expression patterns correspond to the situation in PMF patients 
and potentially discriminate pre-PMF from ET. It would further be worthwhile to 
evaluate PTPs in context with clinical data from PMF patients. Correlations with 
progression, beneficial or adverse survival, for example, might identify individual 
PTPs of relevance and enable further studies to clarify their function in fibrotic bone 
marrow. 
In this study, increased TC-PTP expression and PDGFRβ‒TC-PTP interaction was 
detected during the progression of myelofibrosis in a PMF mouse model. Which 
functional consequences this interaction has in vivo remains to be clarified. As a 
negative regulator of PDGFRβ signaling, increased PDGFRβ phosphorylation and 
downstream signaling was observed in Ptpn2 knockdown cells in vitro. Conclusively, 
higher cell growth rates were observed in Ptpn2 knockdown cells, although only 
evident under reduced-serum conditions. Reversely, increased TC-PTP expression 
and PDGFRβ‒TC-PTP interaction in vivo presumably implies a counter-regulation of 
PDGFRβ signaling in fibroblasts and reduced fibroblast proliferation. Since this 
notion is not directly conferrable relating to the fibroblast proliferation present in bone 
marrow fibrosis, further analyses are needed to elucidate the precise role of TC-PTP 
during disease progression. It is conceivable that increased TC-PTP expression and 
PDGFRβ‒TC-PTP interaction are plainly a result of increased numbers of fibroblasts 
in the bone marrow. Apart from this, it is very well possible that increased TC-PTP 
expression in fibrotic bone marrow has more pronounced effects on other in vivo 
targets, such as EGFR, STATs or CSF1R.273-276 After all, multiplexed IHC revealed 
TC-PTP expression in various different cell types within the bone marrow. 
Furthermore, there are numerous regulatory mechanisms which orchestrate 
intracellular events, which makes attribution of cause and effect intricate. PTPs 
themselves are regulated by different mechanisms, for example by reversible 
oxidation of cysteine residues in the catalytic domain of PTPs.290 Intriguingly, PDGF 
stimulation in cells was shown to result in the production of reactive oxygen species, 
which leads to cysteine oxidation.291,292 In addition, several PTPs (e.g. PTP1B, CD45 
and PTP-PEST) harbor regulatory serine phosphorylation sites.293-295 
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It has long been recognized that altered RTK expression plays a pivotal role in 
different types of cancer, well characterized examples are EGFR in glioblastoma, 
breast, lung, colorectal, ovarian and other cancers,296 or the BCR-ABL fusion protein 
in CML.190 It is a more recent finding that also deregulation of PTPs contributes to 
the progression of cancer and other diseases, which makes PTPs - in respect of (2) - 
especially interesting as potential molecular targets.297 In addition to an implication 
of different PTPs in cancer, PTP1B has gained special interest as a negative 
regulator of the insulin receptor. PTP1B knockout mice are more sensitive to insulin 
and resistant to obesity.298,299 These findings brought about efforts in the 
development of PTP1B inhibitors for the treatment of type II diabetes, insulin 
resistance and obesity.300,301 
However, development of therapeutic drugs targeting PTPs is considered rather 
difficult, and the work on the development on specific PTP1B inhibitors are 
ongoing.302 The phosphotyrosine binding sites are highly conserved among the 
different PTPs, hence, PTP inhibitors are usually not very selective. Nevertheless, 
this is also a common problem in kinase inhibitors, which block structural homologue 
ATP binding sites in multiple RTKs. Still, kinase inhibitors are being successfully used 
in therapy, a well-established example is imatinib for CML treatment.190,303 In addition 
to potentially evolving progress in the development of specific PTP inhibitors, other 
mechanisms for targeting PTPs could present interesting options. For PTPRs, 
blocking the extracellular domain using antibodies or antibody-fragments would be a 
conceivable approach. Another problem which persists is that most PTPs regulate 
more than one RTK and hence, PTP inhibition influences different pathways. Thus, 
targeting of PTPs must be carefully adopted and evaluated in the biological context 
of the respective PTP. 
TC-PTP is PTP1B’s closest homologue, although, both PTPs have very distinct 
functions. Clear implications of PTP1B in diabetes and obesity and targeting of 
PTP1B raise the question, if TC-PTP qualifies as an equally interesting therapeutic 
target for drug discovery. In the context of PMF fibroblasts, enhanced TC-PTP 
expression is a priori hypothesized to repress cell proliferation, and hence TC-PTP 
inhibition is not reasonable as a treatment option for PMF. Still, therapeutic inhibition 
of TC-PTP is generally relevant in case of overexpression in a pathological context. 
To date, different compounds have been tested for TC-PTP inhibition. A PTP inhibitor 
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(‘PTP inhibitor XIX’), for example, targets TC-PTP but also inhibits CD45 and 
PTEN.304 However, there have been successful attempts to develop a selective 
TC-PTP inhibitor (‘compound 8’), which was also shown to be 8-fold more selective 
for TC-PTP over PTP1B.305 
4.9 Conclusion 
This study aimed at investigating expression, activation and regulation of PDGFRβ 
during the development of PMF in mice. Hence, the bone marrow of Gata-1low mice 
was assessed in a pre-, an early and an overt fibrotic stage. Among the PDGF 
signaling components, especially PDGFRβ and PDGF-B displayed a major increase 
in expression and interaction in early and overt bone marrow fibrosis, with a distinct 
role of PDGFRβ in bone marrow stromal cells. For a comprehensive characterization, 
a PLA was applied as a novel technique to analyze the PDGFRβ activation status in 
situ. With further tissue- and marker-specific optimization, PLA might prospectively 
be a promising tool in diagnosis. Furthermore, the role of PTPs during PMF 
development was assessed in this study, and numerous PTPs were found to be 
differentially regulated in the bone marrow of Gata-1low mice. In particular, TC-PTP 
was identified as a regulator of PDGFRβ signaling during disease development in 
mice. Hence, PTPs represent previously unrecognized contributors to disease 
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